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Enzyme and transporter-mediated drug-drug and herb-drug interactions of the 
antimalarials and HIV antiretrovirals 
（抗マラリア薬、抗 HIV レトロウイルス薬による代謝酵素、トランスポーター
を介した薬物間、ハーブ・薬物間相互作用に関する研究） 
Enoche Florence OGA 
ABSTRACT 
Drug-drug interactions (DDIs) are a major cause of concern during drug treatment 
and may result in clinically relevant or sometimes serious adverse events. Besides 
conventional drug therapy, patients are increasingly utilizing herbal medicines, with 
a resultant increase in the incidence of herb-drug interactions (HDIs) on their 
concurrent use. These DDIs/HDIs may result in changed systemic exposure leading 
to variations in drug response of the co-administered drugs including diminished 
therapeutic effect or toxicity. Although DDIs involving the cytochrome P450 (CYP) 
enzymes are more widely recognized, drug transporters make a significant 
contribution to drug disposition, exerting their effect through pharmacokinetic 
alterations. Induction, inhibition and inactivation of CYP enzymes and transporters 
(especially P-glycoprotein; P-gp, an efflux transporter expressed on the apical 
membrane of intestinal epithelial cells) are the major pathways underlying 
drug–drug interactions. Malaria and HIV/AIDS have become enormous public 
health concerns and are known to share a wide overlap in their socio-economic and 
geographical areas of occurrence, routinely resulting in drug co-administration for 
their management. Also, because of their pandemicity and the need to treat 
concurrent ailments, multidrug therapy is common. However, there is a paucity of 
research on HDIs in malaria or DDIs in malaria and HIV/AIDS co-morbidity. In this 
regard, the study aimed at predicting the likelihood of encountering P-gp-mediated 
and CYP-based DDIs/HDIs during the drug management of malaria and HIV/AIDS. 
It made use of various in vitro, ex vivo and in vivo approaches which have their 
individual merits as well as limitations.  
The study brings new light to the fact that altered therapeutic outcomes might be 
caused by DDIs between the antimalarials (amodiaquin and artesunate) and 
digoxin or other drugs that interact with P-gp. These interactions may be of clinical 
relevance given the high incidence of co-administration of P-gp substrate drugs 
with antimalarials. The HDI study shows that Vernonia amygdalina 
co-administration poses a more clinically significant risk for P-gp-mediated HDIs 
than Carica papaya or Tapinanthus sessilifolius. Importantly, significant in vitro P-gp 
inhibition may not always be replicated in animal models. The findings point to the 
need for comprehensive assessments of HDIs in order to obtain more detailed 
understanding of their impact in human subjects. This would ensure appropriate 
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clinical intervention on co-administration with P-gp substrate drugs, especially 
those with narrow therapeutic index. Finally, the influence of ritonavir and 
nevirapine on the CYP2B6 and -3A4 mediated inhibition of the metabolism of 
artemisinin is strongly suggestive of their DDI likelihood. However, an evaluation 
of their influence on CYP induction might be necessary to obtain their net effect on 
CYPs. The present study indicates the likelihood of P-gp and CYP –mediated 
DDIs/HDIs occurring in malaria and HIV/AIDS therapy, suggesting the need for 
caution in clinical instances. However, further in-depth clinical studies are 
recommended in order to obtain the precise therapeutic consequence. 
 
 
Keywords 
Artemisinin, Cytochrome P450, Drug-drug interactions, Drug-herb interactions, 
Drug metabolism, Drug transporters, HIV/AIDS, Malaria, P-glycoprotein, 
Pharmacokinetics 
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AIMS OF THE THESIS 
 To investigate the potential of certain antimalarial drugs to undergo intestinal 
P-gp-related DDIs when co-administered with agents that are transported by 
the glycoprotein, using rhodamine-123, fexofenadine and digoxin as probe 
P-gp substrates (PAPER I) 
 To examine the interaction of selected herbal extracts with digoxin with the 
view to predict the potential of P-glycoprotein (P-gp) mediated herb-drug 
interactions occurring with P-gp substrate drugs using an in vitro model 
(Caco-2 cell monolayer), an ex vivo (Ussing chamber) and an in vivo (Sprague 
Dawley rats) model (PAPERS II and III) 
 To predict the likelihood of encountering clinically significant 
cytochrome-based drug-drug interactions through CYP inhibition, when 
selected HIV antiretrovirals are co-administered with artemisinin in co-morbid 
malaria and HIV (PAPER IV) 
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1. INTRODUCTION AND LITERATURE REVIEW 
1.1 Malaria  
1.1.1 Pathophysiology and epidemiology 
Malaria is an enormous public health concern, with approximately one-half of the 
world’s population currently at risk. Globally, about 250 million people are 
infected with malaria. Although malaria is a preventable and treatable disease, it has 
a high mortality rate being responsible for an estimated 655 000 malaria deaths in 
2010 1). As illustrated in Figure 1A, sub-Saharan Africa accounts for the majority of 
cases, whereas Asia, Latin America, and some parts of the Middle East and Europe 
are also affected. About 86 % of the victims of malaria deaths globally were of 
children under 5 years of age 2, 3). Apart from its impact on the health of the 
populace, malaria imposes a heavy economic burden on individuals and entire 
economies 4-6) . Malaria is an infectious disease whose parasite is transmitted 
through the bites of infected Anopheles mosquitoes. Malaria is mainly caused by the 
Plasmodium species; P. vivax, P. ovale, P. malariae and P. falciparum. However, most 
cases of severe malaria and related mortality are caused by P. falciparum infection 7, 
8). There are reports of complications occurring in non-falciparum infections as well 
including severe infection and even deaths reported following infections with P. 
vivax and P. knowlesi 9-11). 
11 
 
 
 
 
Figure 1.   A) Adult prevalence of malaria B) Global HIV adult prevalence 
rate   
Source; 12, 13)  
B 
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1.1.2 Conventional Malaria management 
Despite the major advances made, malaria is still regarded as a major global 
infectious disease, with a high pediatric mortality toll, especially in the developing 
world 1). Conventional medicines are a central tool for its management. However, 
other measures are also incorporated. Effective antimalarial treatment includes 
the artemisinin-based combination therapy (ACTs) which form the WHO 
recommended standard treatment for uncomplicated malaria in combination with 
other antimalarials. These artemisinin compounds include artemisinin, artesunate, 
artemether, arteether and dihydroartemisinin. Other antimalarial drug classes 
include the 4-aminoquinolines (chloroquine, amodiaquin), arylaminoalcohols 
(halofantrine, lumefantrine, mefloquine, quinine), 8-aminoquinolines (tafenoquine, 
primaquin), antifolates (sulphadoxine, dapsone, pyrimethamine, proguanil, 
chlorproguanil), respiratory chain inhibitors (atovaquone which is commonly 
combined with proguanil) and antibiotics (azithromycin, doxycycline, 
clindamycin) 14). Because ACTs are the first-line antimalarial treatment, clinical 
antimalarial drugs are usually a combination spanning several of these drug 
classes such as; artemether/lumefantrine, artesunate/amodiaquin, 
artesunate/mefloquine, artesunate/sulphadoxin-pyrimethamine, 
dihydroartemisinin/piperaquine, dapsone/chlorproguanil/artesunate, 
pyronaridine/artesunate etc. Newer antimalarial drug classes are evolving 
including the spiroindolones and the imidazolopiperizines 15, 16). Intermittent 
preventive treatment is widely used among pregnant women, who are a special 
population easily susceptible to malaria 17). This measure provides pregnant 
women with at least two doses of an anti-malarial drug (usually 
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sulphadoxine-pyrimethamine), at each scheduled antenatal visit after the first 
trimester, whether they show symptoms of infection with malaria or not 18). This 
preventive treatment has been shown to substantially reduce the risk of anaemia 
in the mother and low birth weight in the newborn 19).  Several non-drug 
measures are also being utilized in the management of malaria. Insecticide-treated 
bed nets (ITNs) are now a major intervention for the control of malaria 20). They 
are a form of personal protection that has been shown to reduce malaria illness, 
severe disease and death due to malaria in endemic regions. They vary according 
to the net materials and the specific insecticides embedded. Vector control through 
indoor residual spraying interventions and measures that target the larval stages 
of the mosquito are used a common control intervention. 
 
1.2 HIV/AIDS 
Around the world, the HIV epidemic rages on, emerging the greatest challenge 
in global health. However, AIDS-related deaths are decreasing largely due to 
increased access to treatment.  By the end of 2011, 34 million people were living 
with HIV globally (Figure 1B). 0.8% of adults aged 15-49 years worldwide are living 
with HIV, although the burden of the epidemic differs between countries and 
regions 13). HIV/AIDS is a life-long condition and antiretroviral drug therapy is 
typically used. Table 1 illustrates the classification of currently used antiretroviral 
agents. Because standard treatment for HIV/AIDS comprises a combination or 
different classes of antiretrovirals, there is a higher likelihood of encountering DDIs. 
Table 2 illustrates some established and potential drug-drug interactions with HIV 
antiretrovirals
14 
 
 Table 1.  Main classes of HIV antiretrovirals 
 Class Examples Mechanism of action Reference 
1 Nucleoside Reverse 
Transcriptase  
inhibitors 
Abacavir, Didanosine, 
Lamivudine, Stavudine, 
Tenofovir, Zalcitabine, 
Zidovudine 
They interrupt HIV replication cycle through competitive 
inhibition of HIV reverse transcriptase and termination of the 
DNA chain 
21) 
2 Non-nucleoside 
Reverse 
Transcriptase  
inhibitors 
Delavirdine, Efavirenz, 
Etravirine, Nevirapine 
They noncompetitively bind the p66 subunit at a hydrophobic 
pocket distant from the active site of the enzyme, inducing a 
conformational change in the enzyme that alters the active 
site and limits its activity 
22) 
3 Protease Inhibitors Indinavir, Nelfinavir, Ritonavir, 
Saquinavir, Atazanavir, 
Darunavir, Lopinavir, 
Tipranavir, Fosamprenavir 
HIV protease inhibitors function as competitive inhibitors 
that directly bind to HIV protease and prevent subsequent 
cleavage of polypeptides. 
23) 
4 Integrase inhibitors  
Raltegravir, Elvitegravir 
 
They block the integrase enzyme which is used to integrate 
genetic material of the virus into the host cell of the target 
24) 
5 Fusion/Entry 
inhibitors 
Enfuvirtide 
Fusion inhibitors act extracellularly to prevent the fusion of 
HIV to the CD4 or other target cell. 
25) 
6 Chemokine receptor 
antagonists Maraviroc 
Selectively and reversibly binds the CCR5 chemokine 
co-receptor, blocking the V3 loop interaction and inhibiting 
fusion of the cellular membranes 
26) 
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Table 2. Established and potential drug-drug interactions with HIV antiretrovirals 
 
ARV 
Co-administered 
drug 
Effect on ARV/co-administered drug Mechanism Reference 
Ritonavir Digoxin ↑ in AUC and ↓ oral clearance of digoxin Inhibition of P-gp 27) 
Lopinavir/ 
ritonavir 
Rosuvastatin 2-fold ↑ in rosuvastatin’s AUC, 5-fold ↑ in Cmax Inhibition of OATP1B1 28, 29) 
Tipranavir/ 
ritonavir 
Atorvastatin 9-fold ↑ in AUC0-∞ and Cmax of atorvastatin Inhibition of OATP1B1 30) 
Rosuvastatin ↑ of 37 and 123 % in AUC0-∞ and Cmax of rosuvastatin Inhibition of OATP1B1 and BCRP 30) 
Atazanavir/ 
ritonavir 
Telaprevir 20 % ↓ in AUC and 15% ↓ in Cmin of telaprevir 
17% ↑ in AUC and 85% ↑ in Cmin of atazanavir 
Modulation of P-gp and CYP3A4 31) 
Ritonavir Quinine 3.4-fold ↑ in AUC, 2.8-fold ↑ in Cmax of quinine Modulation of P-gp and CYP3A4 32) 
Nevirapine Quinine ↓ of 33.4, 36 and 24.8% in AUC, Cmax and T½ , 
respectively of quinine 
33.3 % ↑ in oral clearance of quinine 
Modulation of CYP3A4 33) 
Nevirapine  Artemether 
/lumefantrine 
Nevirapine significantly induces their CYP 
metabolism 
Modulation of CYP3A4 metabolism of 
the antimalarials 
32) 
Didanosine Quinolones ↓ absorption of didanosine Chelation reaction 34) 
Atazanavir Bosentan ↓ plasma concentration of atazanavir Modulation of CYP3A4 35) 
Lopinavir 
/Ritonavir 
Bosentan ↑ bosentan concentration of up to 48-fold Modulation of CYP3A4 36, 37) 
Saquinavir Ketoconazole Significant ↑ in AUC, Plasma concentration and T½ of 
saquinavir by 37, 94 and 38% respectively 
Modulation of P-gp and CYP3A4 38) 
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ARV 
Co-administered 
drug 
Effect on ARV/co-administered drug Mechanism 
Reference 
Ritonavir Ketoconazole Significant ↑ in AUC, Cp and T½ of ritonavir by 29, 62 
and 31% respectively 
Modulation of P-gp and CYP3A4 38) 
Delaviridine  Rifabutin  50-60 % ↓ in Cp of delaviridine Induction of CYP metabolism 39, 40) 
 Nevirapine  Rifampicin 37% ↓in Cp of nevirapine 
Rifabutin  16% ↓in Cp of nevirapine 
Saquinavir  Rifampicin 80% ↓in AUC of saquinavir 
Nelfinavir  Rifampicin  82% ↓in AUC of nelfinavir 
Amprenavir Rifampicin 81% ↓in AUC of  amprenavir 
Indinavir Bosentan ↑ clearance and ↓ drug concentrations and loss of 
therapeutic efficacy of indinavir 
CYP3A4 and CYP2C9 inductive effects 
of bosentan 
41) 
Indinavir  Carbamazepine  ↓ indinavir Cp to 4–25% of mean population values Induction of CYP metabolism 42) 
Ritonavir  Carbamazepine 70–85% ↑ in serum carbamazepine levels Inhibition of CYP metabolism 43, 44) 
Indinavir  St Johns wort ↓ in indinavir AUC by 57% Induction of CYP metabolism 45) 
Nelfinavir  Ethinyl 
estradiol 
47, 28 and 62 % ↓ in AUC, Cmax and Cmin of ethinyl 
estradiol 
Induction of CYP metabolism 46) 
Ritonavir  Ethinyl 
estradiol 
41 and 32% ↓ in ethinyl estradiol AUC and Cmax 
31% ↑ in terminal rate constant 
Induction of CYP metabolism 47, 48) 
Tenofovir Amphotericin B ↑ in nephrotoxicity Synergy and additive nephrotoxic effect 
of the individual drugs 
 
49) 
 
Ritonavir  Docetaxel  ↓ in plasma clearance of Docetaxel 
↑ in severe docetaxel-related toxicity 
Ritonavir-induced inhibition of CYP3A4 50-52) 
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ARV Co-administered 
drug 
Effect on ARV/co-administered drug Mechanism Reference 
Nelfinavir Phenytoin 29, 21 and 39 % ↓ in AUC, Cmax and Cmin of phenytoin Induction of CYP enzymes 53, 54)  
Efavirenz Ketoconazole 72 % ↓ in ketoconazole Cp Efavirenz and ketoconazole act as 
respective inducer and inhibitor of 
CYP3A4 
49, 55, 56) 
Nelfinavir Omeprazole 36, 37 and 39 % ↓ in AUC, Cmax and Cmin of 
omeprazole 
 53, 57) 
Nelfinavir Atorvastatin 74, 122 and 39 % ↑ in AUC, Cmax and Cmin of 
atorvastatin 
Inhibition of CYP3A4 by nelfinavir 53, 58) 
Nelfinavir Simvastatin 505 and 517 % ↑ in AUC and Cmax of simvastatin Inhibition of CYP3A4 by nelfinavir 53, 58, 59) 
Nevirapine Ketoconazole 63 % ↓ in ketoconazole Cp 49) 
Efavirenz Bexarotene ↓ AUC of efavirenz 
50% ↓ in AUC of bexarotene 
Induction of CYP3A and P-gp by 
bexarotene 
60) 
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1.3 Co-morbidity of Malaria and HIV 
Together malaria and HIV/AIDS cause more than 4 million deaths each year 61). 
There is increasing evidence that where they occur together, malaria and 
HIV infections interact.  Malaria worsens HIV by increasing viral load in adults and 
pregnant women; possibly accelerating progression to AIDS; and potentially 
increasing the risk of HIV transmission between adults, and between a mother and 
her child. In adults with low CD4 cell counts and pregnant women, HIV infection 
appears to make malaria worse. Because of the wide overlap of the regions in which 
these diseases occur, several HIV patients take antimalarials either as prophylaxis or 
for treatment. This increases the likelihood of interactions with drugs used in their 
management. 
 
1.4 General overview of herbal medicine use  
The use of complementary and alternative medicines (CAM) is becoming very 
popular with a widespread increase in its interest and reports of over 40 % of the 
adult population utilizing it. In several cases, complementary medicine is used in 
addition to conventional medicine. Therefore there is an increased tendency for 
DDIs to occur between conventional medicine and the herbal medicines. The scope 
of CAM is wide encompassing naturopathy, ancient healing systems, homeopathy, 
mind-body medicines and biologically based practices. Herbal medicine comprises 
the use of plant parts including the seeds, stems, rhizomes, berries, roots, leaves, 
bark, or flowers for medicinal purposes. Unlike conventional drugs, most herbal 
remedies are a complex mixture of chemical constituents whose bioactive 
components in many instances have not been fully characterized, but have been 
reported to be medicinally efficacious 62). There is a long history of the use of 
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phytomedicines, with herbalism having a long tradition of use outside of 
conventional medicine. Their use has become more established as improvements in 
analysis and quality control as well as advances in clinical research has shown the 
value of herbal medicine in treating and preventing disease 63). In some developing 
countries, up to 80 % of the indigenous populace depend on traditional systems of 
medicine and medicinal plants as their primary source of healthcare 64, 65).  Reports 
show that over 70% of German physicians prescribe phytomedicines and over 75% 
of the German populace have used complementary or natural medicine 66). In 
countries like the United States, an increase in its use has been reported due to 
dissatisfaction with the cost of prescription medications, combined with an interest 
in returning to natural or organic remedies 67). Likewise, plant-based medicines are 
used in several African countries because of their low cost, perceived safety and 
efficacy and lower incidence of adverse effects when compared to orthodox 
medicines 68).  About 148 kinds of Japanese herbal medicines (Kampo medicines) 
have been approved and are enlisted on the National Health Insurance Drug Tariff. 
These medicines are reportedly prescribed by 72-78% of Japanese physicians 69, 70). 
While herbal medicine use is on the increase in some countries, stringent regulatory 
requirements in other countries make it difficult to register herbal medicines, 
therefore their reported limited use 71). For example in the United Kingdom, 
industrial herbal preparations are required to conform to the same regulations as 
conventional medicines, hindering license acquisition for numerous herbals 72). 
Several conventional medicines in use evolved from medicinal plant research from 
where they are synthesized as pharmaceutical preparations. Of note are; 
vincristine (Catharanthus roseus), atropine (Atropa belladonna), quinine (Cinchona 
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sp.), emetine (Cephaelis ipecacuanha), digitoxin and digoxin (Digitalis purpurea), 
ephedrine (Ephedra sinica), artemisinin (artemisia annua), reserpine (Rauwolfia 
serpentina), etoposide (Podophyllum peltatum) among several others.  
 
1.4.1 Herbal medicine use and interactions in Malaria and HIV/AIDS 
Malaria is an important global public health issue with high morbidity and mortality. 
Majority of malarial endemic regions are from the world’s developing economies. As 
a result of the relatively high costs for conventional antimalarials, many patients are 
known to take herbal remedies for its prevention and treatment 73). Herbal remedies 
commonly used in the management of malaria include Vernonia amygdalina, Piper 
longum, Tapinanthus sessilifolius, Carica papaya, Azadiractha indica, Curcuma longa, 
Echinacea purpurea and Phyllanthus niruri. Sometimes these herbs are used alone 
or in combination with orthodox medicines, with reports on the wide use of herbal 
remedies in the management of malaria 74-78). For instance, in certain communities, 
extracts from plants may be used, together with chloroquine, for the treatment of 
malaria 79). Acupuncture has also been reported to be a means of managing malaria 
offering a relatively cheap and simple treatment method without side-effects 80). Our 
study based on a human Caco-2 model revealed that extracts of Vernonia amygdalina, 
Tapinanthus sessilifolius and Carica papaya which are herbals commonly used in 
traditional malaria therapy signiﬁcantly inhibited P-gp mediated digoxin transport 
81). Findings from that study suggested that caution should be observed when those 
herbs are concomitantly used with P-gp substrate drugs as they may enhance their 
absorptive transport 81). Frequently, antagonistic effects have been reported on 
co-administration of herbals and orthodox medicines. For instance, although the 
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leaves of Carica papaya are known to exhibit antimalarial effect, the antagonistic 
antimalarial properties when used in combination with artesunic acid in 
Plasmodium berghei-infected mice has been reported 82). In the study, the extracts of 
Carica papaya when solely administered had good antimalarial activity. In a similar 
study, the influence of Eurycoma longifolia extract (a herbal remedy commonly used 
in malaria therapy) was investigated on co-administration with artemisinin (WHO’s 
recommended first-line antimalarial) in experimental mice. Findings from that study 
revealed the suppression of parasitemia in Plasmodium yoelii-infected mice. This is 
suggestive of a promising, potential antimalarial candidate by both oral and 
subcutaneous routes 83). Similar synergistic herb-drug interactions involving 
goniothalamin (Goniothalamus scortechinii)-chloroquine, Vernonia 
amygdalina-chloroquine and curcumin (Curcuma longa)-artemisinin combinations 
have been documented with the suggestion that they be considered for future trials 
in the search for malaria combination therapy 84-86). Also, herbs can be combined for 
their additive effect as shown by the mixture of a Khaya ivorensis -Alstonia boonei 
extract mixture as an antimalarial prophylactic remedy 87). 
Numerous HIV/AIDS patients look towards complementary and alternative 
medicine, and are known to take herbal medicines in order to boost immunity, treat 
complications, or ease side effects from HIV drugs 88).  However, it is of importance 
to thoroughly investigate the potential alterations in pharmacokinetic and 
toxicological profiles when co-administration occurs as their concurrent use has 
resulted in both beneficial and detrimental effects. Their use varies across 
geographical and economic regions, with patients being more likely to incorporate 
traditional and conventional medicine (when available) in areas where there is 
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limited access to these antiretrovirals 89. However, these medicines may not be 
completely safe as some detrimental herb-drug interactions involving the 
antiretrovirals have been reported. In addition, because the current treatment for 
HIV/AIDS comprises a cocktail of individual antiretroviral drug therapies, 
complicated interactions may occur. For instance, St Johns wort and garlic are 
known to interfere with HIV medications. Several other herbal medicines are used 
by HIV/AIDS patients including Hypoxis hemerocallidea (African potato), 
Sutherlandia frutescens, Allium sativum, Eucalyptus globulus, Aloe vera, Trigonostema 
xyphophylloides, Vatica astrotricha, Vernonia amygdalina, Lippia javanica, Bidens 
pilosa, Peltoforum africanum, Hypoxis hemerocallidea and Moringa oleifera 90-93). 
However, the likelihood of their interactions occurring with conventional medicines 
has not been fully elucidated. For instance, Sutherlandia frutescens has been 
reported to inhibit the metabolism of atazanavir in human liver microsomes which 
may have important implications on the absorption and metabolism and the 
overall oral bioavailability of atazanavir 94). Also the protease inhibitor; ritonavir 
on co-administration with some herbal components has been shown to modulate 
P-gp as well as CYP 3A4. In particular, the herbal constituents; kaempferol and 
quercetin (from several plants), hypericin (Hypericum perforatum) and allicin 
(Allium sativum) inhibit the efflux and CYP3A4-mediated metabolism of xenobiotics 
in vitro and may interact with HIV antiretrovirals that are P-gp or CYP 3A4 
substrates, such as ritonavir 95, 96). St. John's wort has been reported to potently 
alter the pharmacokinetics of indinavir (a protease inhibitor and a known CYP450 
substrate) via induction of CYP 3A by St. John's wort. A study revealed a large 
reduction in indinavir concentrations by concomitant St John's wort. This finding 
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has important clinical implications for HIV-infected patients receiving the two 
agents since low plasma concentrations of protease inhibitors are a cause of 
antiretroviral resistance and treatment failure 45).  Garlic is another herbal remedy 
commonly utilized by HIV/AIDS patients. Although some studies have shown that 
garlic has the potential to induce CYP isoenzymes, consequently reducing the 
effectiveness of antiretroviral drugs, in vitro assessments of its effect on CYP450 are 
conflicting 97, 98). In a clinical study, garlic was shown to reduce the plasma 
pharmacokinetic concentrations of saquinavir by altering CYP3A4 isoform of the 
CYP450 enzyme system, the isozyme through which saquinavir is 
metabolized recommending patient caution on concomitant administration 99). Table 
3 illustrates some theoretical and clinically relevant HDIs involving the antimalarials 
and HIV antiretrovirals.
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Table 3. Herb-drug interactions involving the antimalarials and HIV antiretrovirals 
 
S/No. Indication 
Conventional 
drug 
Herbal medicine Effect  Reference 
1 Malaria Chloroquine 
Halofantrine  
Khaya grandifoliola 
Enhanced antiplasmodial effect in infected mice 
Significant ↑ in parasite clearance  
100) 
Quinine 
Mefloquine 
Artemisinin from 
Artemisia annua 
Synergistic effect in an in vitro assay 101) 
2 HIV/AIDS 
Saquinavir Garlic (Allium sativum) 
Signiﬁcantly decreases the systemic exposure in humans 
↓ mean saquinavir AUC by 51% 
↓ Cmax by 54% 
45) 
Indinavir St. Johns wort 
↓ AUC0-8 of indinavir decreased by a mean of 57% in 
humans 
49-99% ↓ in concentration 8 hr post-dosing 
↓ in the mean Cmax of indinavir from 12·3μg/mL to 8·9 
μg/mL 
99) 
Nevirapine St. Johns wort Clearance of nevirapine ↑ by 35% # in humans 102) 
Protease 
inhibitors 
SP-303 (an extract of  
Croton lechler) 
Significant reduction of stool weight and stool frequency in 
AIDS patients who had diarrhea 
103) 
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1.5 Enzyme and Transporter-mediated drug interaction 
1.5.1 Xenobiotic Transporters  
Drug transporters are expressed in various tissues and play a significant role in the 
influx and efflux of drugs, xenobiotics and toxins across cells. They influence drug 
disposition by modulating their pharmacokinetics 104). Several studies have focused 
on the identification and characterization of drug transporters with regards to their 
expression in tissues, mechanisms of transport, characterization of their substrates 
and inhibitors, species differences, and genetic polymorphisms 105-107). The 
ATP-binding cassette (ABC) and solute carrier (SLC) transporters are the main 
divisions of drug transporters. The ABC superfamily comprises the largest class of 
transporters. These transporters use the binding and hydrolysis of ATP to power 
the translocation of a vast substrate range across membranes 108). Clinically relevant 
ABC transporters include breast cancer resistance protein, BCRP (ABCG2); bile salt 
export pump, BSEP (ABCB11); P-glycoprotein, P-gp/multidrug resistant protein 1, 
MDR1 (ABCB1); multidrug resistant protein 3, MDR3 (ABCB4); multidrug 
resistance-associated protein 2, MRP2 (ABCC2); multidrug resistance-associated 
protein 3, MRP3 (ABCC3) and multidrug resistance-associated protein 4, MRP4 
(ABCC4) 28). The SLC superfamily consists of major uptake transporters responsible 
for xenobiotic transport and includes organic anion–transporting polypeptide 1B1, 
OATP1B1 (SLCO1B1); organic anion–transporting polypeptide 1B3, OATP1B3 
(SLCO1B3); organic anion transporter 1, OAT1 (SLC22A6); organic anion 
transporter 3, OAT3 (SLC22A8); organic cation transporter 2, OCT2 (SLC22A2); 
organic anion–transporting polypeptide 1A2, OATP1A2 (SLCO1A2); organic 
anion–transporting polypeptide 2B1, OATP2B1 (SLCO2B1); organic cation 
transporter 1, OCT1 (SLC22A1); Peptide transporter 1, PEPT1 (SLC15A1); Peptide 
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transporter 2, PEPT2 (SLC15A2); multidrug and toxin extrusions 1, MATE1 
(SLC47A1) and multidrug and toxin extrusions 2, MATE2-K (SLC47A2) 109, 110 ). 
ATP-binding cassette transporters are known to function as barrier proteins 
extruding toxins and xenobiotics out of cells. Of these, P-glycoprotein (P-gp) is an 
efflux transporter expressed on barrier epithelia including the intestine, kidney, 
liver and blood-brain barrier where it mediates transport across cell membranes 
111).  P-gp is the transporter of interest in this study. It is a determinant in the 
pharmacokinetics, efficacy and toxicity of xenobiotics. Figure 2 illustrates the 
localization of transporters in the intestinal epithelial cells, hepatocytes and renal 
tubular cells, which are in the main organs influencing drug disposition. With 
specific reference to the antimalarials, several transporters have been implicated in 
the disposition of some of them. Mefloquine has been shown to inhibit the function 
of P-glycoprotein in drug-resistant individuals 112). In mediating the final excretion 
step of cationic drugs into bile and urine, of particular importance are the Multidrug 
and toxin extrusion (MATE; SLC47A) proteins which mediate the translocation of 
organic cations in exchange with protons across membranes proteins. These 
transporters are known to influence the disposition of several drugs including the 
antimalarial drugs; chloroquine and quinine 113). Also, the antimalarial agent 
pyrimethamine is a potent MATE1 and MATE2-K inhibitor 114). 
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Figure 2.   Localization of transporters in major drug disposition organs 
 
 
1.5.2 Cytochrome P450 enzymes 
Cytochrome P450 is a large and diverse group of isozymes responsible for the 
catalysis and biotransformation of several drugs.  They perform this function by 
oxidizing, hydrolyzing or reducing the drugs, enabling conjugation enzymes to 
attach polar groups to make the metabolites water soluble easy excretion. Of the CYP 
isoforms, CYP3A4 is the most abundant. There is increasing evidence that the CYP 
isozymes contribute to the variability in drug response (incomplete cure, relapse, or 
resistance) or toxicity experienced with antimalarial drugs 115). As instances, there is 
a clear association between concentrations of proguanil within plasma and certain 
genetic polymorphisms of CYP2C19 116), and genetically established levels of 
CYP2C8 might have important clinical implications in the toxicity of amodiaquin 117, 
118). Variation in the expression of drug-metabolizing enzymes 
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and transport proteins affects the pharmacology of antimalarial drugs. Exploration 
of pharmacogenetics might help to optimize the use of antimalarial drugs. 
 
1.5.3  Influence of transcriptional regulators 
Several CYPs and transporters that influence drug disposition can be induced by 
xenobiotics and herbs 119). The nuclear receptors; pregnane X receptor (PXR) and 
the constitutive androstane receptor (CAR) which are present in the small intestine 
and liver have emerged as transcriptional regulators of cytochrome P450 
isoenzymes (especially CYP 3A, -2B6, -2C8, -2C9 and -2C19) and drug transporters: 
P-gp, MRP2 and OATPs 120, 121). Besides the various xenobiotics that have been 
reported to activate PXR, herbals including St. Johns Wort are known to potently 
induce it 122).  These nuclear receptors also enhance the expression of phase II 
conjugating enzymes like UDP-glucuronosyl transferase, sulfotransferase and 
glutathione-S-transferase enzymes 123, 124). As a result of an increased induction of 
these nuclear receptors, there is an enhanced expression of P-gp and CYP enzymes 
which are likely to reduce the rate of absorption and increase the rate of 
elimination of drug substrates. 
 
1.6 Models of drug absorption and transport 
The intestine plays a vital role in the absorption of xenobiotics including drugs and 
toxins. In the intestine, uptake transporters including OATPs and PEPT1 are 
involved in drug absorption whereas P-gp, BCRP and MRPs function as efflux 
transporters. Co-administered drugs may inhibit or induce these transporters. After 
oral administration, the inhibitor concentration in the intestine can be much higher 
than that in systemic circulation. This may cause DDIs in the intestine rather than 
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in the liver on oral administration even at therapeutic doses 125). Several methods 
for predicting the likelihood of occurrence of intestinal enzyme and 
transporter-mediated DDIs have been suggested 126-128). Figure 3 depicts the main 
transport mechanisms across the intestinal wall. Several transport models have 
been developed which simulate the different transport mechanisms. These 
experimental models of permeability routinely utilize cell monolayers, artificial 
membranes (e.g. parallel artificial membrane permeability assay), excised tissues 
and animals. These studies are of vital importance especially in drug discovery and 
development as they allow prediction of in vivo intestinal absorption 129). Different 
assay techniques, variability in animal species, tissue sources, and cell types usually 
give differing correlation between the measured human effective permeability 
values and the extent of absorption of drugs in humans determined by 
pharmacokinetic studies 129, 130) 
 
Figure 3.   Transport mechanisms across intestinal epithelial cells 
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1.6.1 Cell monolayers 
Although several cell monolayers (MDCK, HT-29, T-84 and Caco-2) can be used to 
study intestinal absorption as well as other functions of differentiated intestinal 
cells, Caco-2 cell monolayers are a widely accepted model for such studies including 
P-gp investigation 131, 132). The human intestinal Caco-2 cell line  has been 
extensively used over the last twenty years as a model of the intestinal barrier 133). 
Although they originated from human colon adenocarcinoma cells, they closely 
resemble intestinal epithelial cells as demonstrated by the formation of a polarized 
monolayer, tight junctions, well-defined brush border on the apical surface 134). As 
illustrated in Figure 4, because of the Transwell™ inserts cultured with Caco-2 cells 
closely resemble in vivo intestinal conditions, Caco-2 cells are widely used to 
predict drug absorption patterns because they retain several morphological and 
functional properties of enterocytes 135). 
 
 
Figure 4.   P-gp localization in the enterocyte and Caco-2 cell monolayer 
An illustration of the similarity in P-gp expression between a Caco-2 cell monolayer 
grown on a Transwell insert and the intestinal epithelia 
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However, drug transporter expression and the tightness of tight junctions may differ 
between Caco-2 cells and the human intestine, which may affect drug permeability. 
136) . Several permeability assays have been conducted for predicting the in 
vivo absorption of drugs across the intestinal wall by measuring the rate of 
transport of a compound using the Caco-2 cell model 137, 138). In this, bidirectional 
studies of transporter interactions across the cell monolayer (apical-to-basolateral 
and basolateral-to-apical) can be assessed as illustrated in Figure 5. This enables 
the computation of the efflux ratio which is an indicator as to whether a compound 
undergoes active efflux. Caco-2 monolayers show good expression of transporters, 
including phase I and phase II enzymes. However, CYP3A, which is present in 
almost all intestinal cells, is very weakly expressed in Caco-2 cells 134). P-gp is the 
transporter most studied using Caco-2 cells. Most P-gp studies utilize digoxin or 
rhodamine-123 as probe substrate. Verapamil, cyclosporin A or quinidine are 
commonly included as inhibitors to identify whether active transport is mediated 
by P-gp 139). 
 
 
Figure 5.   Techniques for transporter interactions in Caco-2 cell 
monolayers 
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1.6.2 Membrane vesicles expressing transporter cDNA 
ABC transporters transport substrates across the cell membrane against their 
concentration gradient. These transporters include BCRP, BSEP, MRP1, MRP2, MRP3, 
MRP4 and P-gp. In order for this transport to be achieved, ATP hydrolysis is needed 
as an energy source. Inside-out vesicles are now commonly being used to study of 
the interaction of drugs with the transporter of interest. As depicted in Figure 6, 
these vesicular assays enable the evaluation of transporter activity by measuring 
transport of drug substrates from the reaction medium into the vesicles 140). The 
drugs can then be quantified by fluorescence, liquid scintillation counting or 
chromatographic analysis. 
 
 
Figure 6.   An inside-out vesicle 
 
 
1.6.2 Artificial membranes 
Artificial membranes are used as a model for intestinal permeability as they are 
high throughput, reproducible and low cost alternative for in vitro assessment 141). 
The immobilized artificial membrane (IAM) and parallel artificial membrane 
permeation assay (PAMPA) are the commonly used models. The lack of enzymes, a 
lipid bilayer, transporters and active transport pathways are their main limitation. 
In addition, the UV-based PAMPA model requires UV absorbance, which many 
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compounds do not exhibit. PAMPA enables test compounds to be ranked based on a 
simple permeability property (passive, transcellular permeation) as it avoids the 
complexities of active transport. It is more commonly used and has become popular 
in the pharmaceutical industry as a tool for primary pharmacokinetic screening of 
research compounds 142).  
 
1.6.3 The Ussing chamber 
The Ussing chamber is a model used to examine absorption across various 
epithelial membranes. Besides being used for transport and toxicology studies 
across excised tissue sections, it can also be utilized on filter grown cell monolayers. 
Attempts have been made to develop in situ and ex vivo models that more closely 
replicate intestinal absorption in humans; however, the data obtained from studies 
using such models may be limited 130). The likelihood of DDIs/HDIs occurring can be 
studied by monitoring drug absorption when co-administered with various herbs. 
Sections of intestinal mucosa mounted on Ussing chambers are useful tools for 
analyzing such changes in drug absorption, and the results obtained using this 
model are reported to have more merits than those obtained using Caco-2 cells or 
parallel artificial membrane permeability assay models. Furthermore, the 
expression levels of drug transporters and drug-metabolizing enzymes in the Ussing 
chamber system are comparable to those in vivo and the morphological structure of 
the intestine is preserved 143, 144). Our study utilized excised rat ileal segments in 
which P-gp is highly expressed on the apical side of the epithelial cells 145, 146). The 
ileum was specifically chosen as the level of absorptive-directed transport is higher 
in this segment than in other intestinal segments 147). Figure 7 is a diagrammatic 
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representation of the basic design of the Ussing system. The Ussing chamber closely 
depicts the physiological system as the presence of a gas manifold provides air 
regulation to both sides of each chamber. Temperature is maintained utilizing a 
heater block, connected to a circulating water bath. It basically comprises 2 
chambers- a mucosal and a serosal compartment. The excised intestinal tissue is 
carefully pinned in such a way to be bathed by the buffer (commonly Krebs Ringers 
bicarbonate buffer). Detailed description of the Ussing system and its application 
has been reported 148, 149). 
   
Figure 7.   Ussings chambers  
Source: 150) 
 
 
1.6.4 In situ single-pass perfusion models 
In situ models of intestinal perfusion of the intestine are commonly used as models 
to determine and compare the absorption characteristics of drugs. It enables easy 
determination of regional drug disposition. Normally, the animal of choice is 
anaesthetized and laparotomy conducted to provide access to the abdominal cavity 
(Figure 8). The investigated drug can then be introduced into the intestinal segment 
of interest either through a closed or opened loop. Comparison of the relative 
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contribution of intestine versus liver in the disposition of a specific compound can 
be determined using this model, further allowing the enteric and enterohepatic 
recycling of drugs to be examined 151). 
 
Figure 8.   Close-loop perfusion model 
 
 
1.6.5 In vivo animal models 
Drug absorption studies in animals are widely believed to be good predictors of 
human absorption. The rat is the most commonly used animal model in the 
transport studies, mainly because it better reflects the human situation with respect 
to paracellular space and metabolism 152, 153).  Rats are a valuable animal model to 
assess pharmacokinetic drug interactions and data obtained from studies using rats 
has been used to justify the clinical use of specific drugs 154, 155). In vivo animal 
models normally provide good correlation with human absorption patterns as they 
incorporate the dynamic components of the mesenteric blood circulation, the 
mucous layer and all the other factors that can influence drug dissolution 134). 
However, studies utilizing animals also have limitations including the provision of 
little mechanistic information on drug absorption; therefore they tend to provide 
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false-positive results. Because of these demerits the best model for human 
experiments are actually humans. 
  
1.7 Models of drug metabolism  
1.7.1 Microsomal and sub-cellular fraction assays 
Currently, several studies utilize microsomes, S9 and cytosol fractions as a major 
tool for studying CYP inhibition, CYP phenotyping, clearance, and metabolite 
characterization. Microsomes are responsible for the biotransformation of drugs, 
toxins and xenobiotics, enabling for metabolic investigations. Phase I and phase II 
reactions are the main pathways for enzyme reactions in drug metabolism. Phase I 
enzymes include the CYPs processes of oxidation, reduction and/or hydrolysis and 
require NADPH as a cofactor. In addition to factors for phase I metabolism, 
microsomes also possess Phase II enzymes such as glutathione S-transferases, 
epoxide hydrolase, and UDP-glucuronyl transferase which act predominantly on 
Phase I altered compounds to facilitate excretion. They can therefore be used to 
evaluate Phase I and Phase II metabolism. In addition to factors for phase I 
metabolism, microsomes also possess Phase II enzymes such as glutathione 
S-transferases, epoxide hydrolase, UDP-glucuronyl transferase, 
flavin-monooxygenases and carboxylesterases which act predominantly on phase I 
altered compounds to facilitate excretion. They can therefore be used to evaluate 
phase I and phase II metabolism. These microsomes may be extracted from the 
liver or extrahepatic tissues like the intestine, lungs or kidney. Hepatic and 
intestinal-derived tissues evaluate the potential of pre-systemic metabolism which 
may ultimately influence the bioavailability of a drug. The intestinal mucosa has 
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been reported to be the most important extrahepatic site of drug biotransformation, 
appreciably expressing CYPs 156). Renal and pulmonary-derived cells allow for an 
examination of extrahepatic metabolism. Depending on which species they are 
derived from, the microsomal system allows for the investigation of interspecies 
differences in metabolism, permitting a comparison of metabolic profiling in guinea 
pigs, minipigs, rats, mice, trout, rabbits, dogs, monkeys and humans.  
 
1.7.2 Hepatocyte assays 
Liver hepatocytes are valuable and effective tools for the in vitro evaluation of drug 
interactions, intrinsic clearance, metabolism, metabolic profiling, hepatotoxicity, and 
transporter activity.  In addition to the evaluations which microsomal assays cover, 
they also allow for studies of transporter activity and drug induction, which cannot 
be assessed in microsomal systems. Hepatocytes are known to possess all the 
hepatic drug metabolizing enzymes within an intact cell. Interspecies differences 
can also be assessed by the use of species-specific cryopreserved. Because 
hepatocytes have in vivo-like enzyme expression levels, it is easier to correlate in 
vitro/in vivo data. Fresh hepatocytes, cryopreserved hepatocytes are routinely used. 
HepG2 cells are also widely used as they are a suitable in vitro model system for the 
study of polarized human hepatocytes. Recently systems, including HepaRG™ cells 
(terminally differentiated hepatic cells derived from a human liver progenitor cell 
line) are gaining interest, as they maintain the morphology, expression of key 
metabolic enzymes, nuclear receptors, and drug transporters which are exhibited 
by primary human hepatocytes 157).   
 
38 
 
1.8 Mechanisms of herb-drug interactions 
Herb-drug interactions (HDIs) can occur when herbal and conventional medicines 
are co-administered, and the possible changes in pharmacokinetic disposition as 
well as the pharmacodynamic impact of such interactions need to be investigated 
158, 159). Several HDIs have been reported including the influences of St. John’s wort, 
ginseng, gingko, and milk thistle when they are co-administered with conventional 
medicines 160, 161). The majority of these HDIs interfere with cytochrome P450 
enzymes 162). Although reports concerning the influence of HDIs on xenobiotic 
transporters are limited, the impact of HDIs on permeability glycoprotein (P-gp) is 
slowly gaining interest 163-165). P-gp is an efﬂux protein that pumps its substrates 
out of cells in an ATP-dependent manner, thereby reducing the intracellular 
accumulation of these substrates 28). P-gp is expressed on the apical membrane of 
epithelial cells where it extrudes several orally administered drugs into the 
intestinal lumen and thereby interferes with drug disposition 166, 167). Inhibition of 
P-gp is of great clinical interest as this can enhance the oral bioavailability of 
specific drugs and reverse multidrug resistance (MDR). However, the mechanisms 
and potential influence of HDIs on P-gp are not fully understood. 
Pharmacokinetic and pharmacodynamic alterations are the two mechanistic 
pathways through which herb-drug interactions (HDIs) occur, resulting in 
beneficial or toxic responses. Figure 9 illustrates the mechanisms of HDIs. Majority 
of the HDIs manifest as a result of pharmacokinetic alterations. This arises from 
changes in the function and expression of transporters or enzyme that mediate the 
absorption and elimination of drugs in the small intestine, kidney and liver 92). 
Numerous pharmacokinetic interactions involving herbal remedies which are 
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mediated by transporters and enzymes have been documented. In addition to the 
cytochrome enzymes, membrane transporters are known play an important role in 
the modulation of absorption, distribution, metabolism and excretion of drugs 28).  
 
Figure 9.   Main mechanisms for herb-drug interaction 
 
 
1.8.1 Enzyme-mediated HDIs 
One of the most important causes of clinically-relevant HDIs is the inhibition or 
induction of the activity of cytochrome P450, a superfamily of enzymes catalyzing 
extremely diverse and often complex reactions in the metabolism of numerous 
drugs, phytomedicines and xenobiotics. Majority of the drugs are metabolized by or 
interact with the isoform CYP 3A. For instance, several intestinal CYP 3A inhibitors 
(including the triterpenes; maslinic acid, corosolic acid, and ursolic acid) have been 
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isolated from Vaccinium macrocarpon (cranberry). Cranberry is now commonly 
taken as a treatment for urinary tract infections due to a group of 
proanthocyanidins which exhibit bacterial anti-adhesion activity against both 
antibiotic susceptible and resistant strains of uropathogenic Escherichia coli 
bacteria 168).  Another study revealed that cranberry juice inhibits 
the CYP3A-mediated metabolism of nifedipine altering its pharmacokinetics by 
increasing the concentration of nifedipine in rat plasma. The study demonstrated 
that the oxidation activities of nifedipine in rat intestinal and human hepatic 
microsomes were inhibited after pre-incubation with cranberry juice 169). Similarly, 
the widely used herbal remedy, Echinacea purpurea has been reported to 
significantly induce CYP 3A 170). It has been shown to selectively modulate the 
catalytic activity of CYP3A at hepatic and intestinal sites suggesting that CYP 3A 
substrates with relatively high bioavailability may be more susceptible 
to Echinacea-mediated interactions 171, 172). As CYP 3A is the main drug 
metabolizing enzyme, the potential of HDIs occurring with Echinacea purpurea 
may be high. 
 
1.8.2 Transporter-mediated HDIs 
Although most studies have focused on cytochrome-based drug interactions, the 
influence of transporters as a mechanism for DDIs is increasingly being 
documented, as it has been revealed that they can play an important role in 
modulating drug absorption, distribution, metabolism and elimination. Xenobiotic 
transporters are generally categorized into the ATP Binding Cassette (ABC) and 
solute carrier (SLC) superfamilies. The ABC transporters function as barrier 
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proteins extruding toxins and xenobiotics out of cells. They include P-gp, breast 
cancer resistance protein (BCRP), bile salt export pump (BSEP) as well as several 
multidrug-associated resistance proteins (MRPs). They are commonly expressed on 
barrier epithelia where they mediate transport across cell membranes 28). These 
transporters are significant determinants of the pharmacokinetics, efficacy and 
toxicity of xenobiotics including phytomedicines and co-administered drugs may 
inactivate, inhibit or induce these transporters. Of all the transporter-mediated 
HDIs, P-gp is the most implicated. There are reports on the modulation of P-gp by 
herbs such as St. John’s wort, Vernonia amygdalina, Tapinanthus sessilifolius, Coptis 
chinensis, Ginkgo biloba, Piper nigrum and Glycorrhiza glabra 81, 92, 164 ).   
On the other hand, the SLC transporters mainly comprise of uptake transporters 
including the OATPs, organic cation transporters (OCTs), organic anion transporters 
(OATs), peptide transporters (PEPT) and multidrug and toxic compound extrusion 
transporters (MATE) 28). These SLC transporters are known to facilitate absorption 
of phytomedicines and xenobiotics into the systemic circulation. Because 
transporters are mainly expressed in the intestinal epithelial cells and organs of 
elimination (kidney proximal tubules and liver hepatocytes), they are known to 
significantly influence the disposition of herbal remedies 173). Fewer reports 
investigate the influence of SLC-mediated herb-drug interactions when compared 
to ABC transporters. For example, baicalin from Radix scutellariae showed a 
reduction in the plasma concentration of rosuvastatin when co-administered as a 
result of OATP modulation 174). In the study, the observed decrease in the plasma 
concentration of rosuvastatin in the presence of baicalin was thought to be partially 
mediated by baicalin’s induction of hepatic rosuvastatin uptake through OATP1B1 
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174). Another study reported that the pharmacokinetic disposition of salvianolic acid 
B was altered by rifampicin in rats due to the inhibition of Oatp-mediated influx 175). 
Salvianolic acid B is one of the most bioactive components of Salvia miltiorrhiza, a 
traditional Chinese herbal medicine that is commonly used for prevention and 
treatment of cerebrovascular and cardiovascular disorders. Likewise, several herbs 
modulating OAT1, a transporter actively involved in renal active secretion have been 
reported. Among 63 Chinese herbal medicines examined in the study, only two 
exhibited significant inhibitions on hOAT1-mediated [3H]-p-amino hippuric acid 
uptake in vitro as well as p-amino hippuric acid clearance and net secretion in vivo 
176). 
 
1.8.3 Dual enzyme- and transporter-mediated HDIs 
Some phytomedicines are known to influence both transporter and cytochrome 
function. P-gp and CYP 3A4 both constitute a highly efficient barrier for many orally 
absorbed drugs with a wide overlap in their substrates 177). Rhodiola rosea, a 
phytomedicine used in the management of  depression has shown potent 
inhibition of both P-gp and CYP 3A4 178). Also, St. John’s wort (Hypericum 
perforatum), one of the most widely used herbal remedies with several medicinal 
effects including its recognized antidepressant properties, induces both CYP 3A and 
the efflux transporter; P-gp 179). In another study, quercetin and rutin which are 
popular herbal flavonoids induced the functions of both P-gp and CYP3A4 by 
decreasing the bioavailability of cyclosporin when co-administered 180). These 
alterations on normal P-gp efflux and CYP activity has an impact on the 
pharmacokinetic disposition of CYP 3A and P-gp substrate drugs when 
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co-administered leading to changes, including lower efficacy and/or the emergence 
of toxicity 181). 
 
1.9 Transporter substrate and inhibitor probes  
1.9.1 Digoxin 
Digoxin is a well-known probe drug that is used to investigate P-gp function. It was 
used in this study because it is selectively transported by P-gp, not by other 
xenobiotic transporters 182, 183). Digoxin also has the advantage of not being 
extensively metabolized, allowing for the selective study of P-gp function. The 
elimination of digoxin is dependent on P-gp that it is routinely used as a control to 
investigate the influence of other drugs on P-gp activity. Digoxin also provides a 
clinically relevant example as it has a narrow therapeutic index. Therefore its use 
may make a case for other drugs with low safety margins. It is important to note 
that for digoxin, even a 25% increase in exposure is viewed as clinically relevant, 
because toxicity may occur as a result of increased drug levels 166).  
 
1.9.2 Fexofenadine 
Fexofenadine is an antihistamine that exhibits good oral bioavailability despite its 
efflux by P-gp as reported using various models 184, 185). Other reports show that 
multiple uptake and efflux transporters play a role in its intestinal and hepatic 
disposition, including BSEP, OAT3, OATP1B1, OATP1B2, OATP2B1, MRP2, MRP3 and 
P-gp 186). It undergoes minimal metabolism, as over 95% of an administered dose is 
recovered intact in urine and feces 185). This characteristic allows for drug transport 
studies alone without factoring in the influence of metabolizing enzymes. Despite its 
modulation by several transporters, it is still of value as a probe of P-gp-mediated 
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transport, especially in studies investigating drug-drug interaction and disposition. 
 
1.9.3 Rhodamine-123 
Rhodamine-123 (Rho-123) is an easy-to-use, cationic fluorescent marker utilized to 
study the function of P-gp in both multidrug-resistant cells and normal tissues 
including the intestine187). It is commonly used because of its relatively cheap cost 
and since it fluoresces, it can be detected easily. Since the expression and function 
of P-gp in some cells are the high, Rho123 accumulation is widely used as a 
surrogate indicator to evaluate the degree of functional inhibition of P-gp in trials of 
P-gp inhibitors. It was utilized in the initial phase of this study for the preliminary 
screening of antimalarials as P-gp inhibitors, before further experimentation with 
clinically relevant substrates. 
 
1.9.4 Verapamil 
Verapamil is commonly used in drug transport studies as either a substrate or 
inhibitor of the drug efflux pump; P-gp. In this study, it was utilized as an inhibitor 
of P-gp, as its potent inhibitory effect has been severally reported 188). It undergoes 
extensive oxidative metabolism mediated by CYP, especially CYP3A4, with less than 
5% being excreted unchanged in urine after oral administration 189). In instances 
where P-gp is inhibited, there is an enhanced absorption of the drug through the 
enterocytes, with a resultant increase in plasma concentration. Also, a drug that is 
normally eliminated by P-gp in the bile or urine will accumulate in the body when 
P-gp is inhibited. Inhibition of P-gp by verapamil has been responsible for several 
clinical drug-drug interactions. For instance, the interaction between digoxin and 
verapamil which takes place at P-gp located in the liver and kidneys, reduces the 
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excretion of digoxin 190). Therefore, the introduction of verapamil as an inhibition 
control in evaluating P-gp mediated drug interactions is common, and was utilized 
in this study. 
 
1.9.5 Cyclosporin A 
Cyclosporin has also been used in studies as a potent inhibitor of P-gp 191). It has 
been shown to reduce the renal clearance when concurrently administered with 
digoxin 192). In addition to verapamil, we included cyclosporin A as an inhibition 
control in our study utilizing the Ussing chamber. However, cyclosporin A is not 
selective to P-gp, as it has been shown to modulate the activity of BCRP, MRP1 and 
lung resistance protein (LRP) 193). 
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2. MATERIALS AND METHODS 
2.0 Materials.  
Amodiaquin (ADQ), DIG, VER, sulphadoxin (SDX), chloroquine (CQ), artemisinin 
(ASN), and artesunate (ART) were purchased from Sigma-Aldrich (St Louis, MO, 
USA). Artemether (ATM) was obtained from Tokyo Chemical Industry Co., Ltd. 
(Tokyo, Japan); lumefantrine (LUM) was obtained from May & Baker (Lagos, 
Nigeria); QD was obtained from Wako Pure Chemical Industries, Ltd. (Osaka, Japan); 
[3H]-DIG (40 Ci/mmol) was purchased from PerkinElmer (Boston, MA, USA); and 
rhodamine-123 (Rho-123) was purchased from Acros Organics (Somerville, NJ, 
USA). All other chemicals and reagents were of the highest analytical grade available. 
Curcumin extract (from Curcuma longa) and unlabeled DIG were purchased from 
Sigma-Aldrich Co. (St Louis, MO, USA). Verapamil (VER) was from Wako Pure Chem. 
Industries Ltd. (Osaka, Japan). 3H-DIG (40Ci/mmol) was purchased from 
PerkinElmer (Boston, MA, USA). Cyclosporin A (CysA) and Verapamil (VER) were 
from Wako Pure Chem. Industries Ltd. (Osaka, Japan). βNADP+, 
Glucose-6-Phosphate (G6P) and Glucose-6-Phosphate dehydrogenase (G6PDH) 
were purchased from Oriental Yeast Co. Ltd (Tokyo, Japan). Ketoconazole (KTZ), 
nelfinavir mesylate, nevirapine and artemisinin were obtained from Sigma (St Louis, 
MO, USA), ritonavir was from Toronto Research Chemicals Inc. (Toronto, Ontario, 
Canada), artemether was from Tokyo Chemical Industry Ltd (Tokyo, Japan), and 
saquinavir was obtained from Roche (Mannheim, Germany). Ethyl acetate, 
acetonitrile (both HPLC grade) and MgCl2 were purchased from Wako (Osaka, 
Japan). All other chemicals and reagents used were of the highest grade and 
commercially available. Pooled human liver microsomes and pooled human 
intestinal microsomes were purchased from Celsis In Vitro Technologies (Baltimore, 
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MD, USA). 
The phytomedicines investigated were bitter leaf (Vernonia amygdalina), neem 
leaves (Azadiractha indica), brimstone bark (Morinda lucida), lemon grass 
(Cymbopogon citratus), pawpaw leaves (Carica papaya), and African mistletoe leaves 
(Tapinanthus sessilifolius). The plant parts were collected from their natural habitat 
in various locations in Jos, Nigeria and were dried under a shade for several days at 
room temperature. The identity of the plants was confirmed at the Forestry 
Research Institute of Nigeria, Ibadan where voucher specimens were deposited. 
 
2.1 PAPER I 
2.1.1 Cell culture.  
Immortalized human colon carcinoma Caco-2 cells (passage #17-43) were routinely 
cultured in Dulbecco’s modified Eagle’s medium (Sigma, St Louis, MO, USA) 
containing 10% fetal bovine serum and 1% antibiotic-antimycotic (Invitrogen, 
Grand Island, NY, USA). Cells were maintained in an incubator at 37°C with 95% 
relative humidity and a 5% CO2 atmosphere. The culture medium was changed two 
to three times weekly. Upon reaching near confluence (80 to 90%), the cells were 
detached from the culture flask by the addition of 0.05% trypsin in 0.02% EDTA. 
Cells were then seeded at a density of 1 x 105 cells/cm2 on Transwell 
collagen-coated membrane inserts (6.5 mm membrane diameter, 0.4 µm pore size, 
0.33 cm2 surface area) that were pre-loaded into Transwell 24-well cluster plates 
(Corning, NY, USA). They were used 18 to 25 days post-seeding in order to obtain 
differentiated monolayers and an anticipated high expression level of transport 
proteins (i.e., P-gp). Monolayer integrity on the permeable membrane was assessed 
by transepithelial electrical resistance (TEER), which was tested using a Millicell 
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ERS-2 Volt-Ohm meter (Millipore, Billerica, MA, USA). Only monolayers with TEER 
values above 200 Ωcm2 were used in the transport experiments. 
 
2.1.2 Transport experiments.  
The transport experiments were conducted in transport medium consisting of 
Hank’s balanced salt solution (HBSS) buffered with 10 mM 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.4) at 37°C. Prior to the 
transport experiments, the monolayers were washed twice with transport medium 
and pre-incubated for 30 min. The test agents were dissolved in < 1% of the 
respective dissolving solvent. Each test agent was added to either the apical (A) or 
basolateral (B) side of the monolayer, with the apical side having a final volume of 
100 µL, and the basolateral side having a final volume of 600 µL. The side of the 
monolayer that received the test agent was termed the donor compartment, while 
the other side was termed the recipient compartment. Samples (50 µL) were taken 
from either the donor or the recipient compartment at time intervals of 30, 60, 90, 
and 120 min, and the removed volume was replaced with a corresponding volume 
of pre-warmed, drug-free HBSS solution at 37°C. To examine the effects of ADQ, ART, 
LUM, ATM, CQ, ASN, and SDX on P-gp-mediated transport, the impact of drug 
addition to both the A and the B side of the monolayer was independently assessed. 
VER (100 µM) and QD (1 µM) were used as positive inhibitor controls. 
 
2.1.3 Quantification of Rho-123 and DIG transport.  
The transport of Rho-123 was quantified using a MTP-600 fluorescence microplate 
reader (Corona Electric, Ibaraki, Japan) equipped with a 490 nm excitation, 590 nm 
emission filter set. For [3H]-DIG determination, a 50 µL sample of transport medium 
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from either the donor or the recipient compartment was mixed with 2 mL of 
Clear-sol I scintillation cocktail (Nacalai Tesque, Kyoto, Japan) and the radioactivity 
was measured with a LSC-6100 liquid scintillation counter (Aloka, Tokyo, Japan). 
 
2.1.5 Quantification of FXD transport.  
FXD analysis was carried out by LC/MS/MS. Samples were analyzed on a hybrid 
triple quadrupole linear ion trap (QTRAP) 4000 LC/MS/MS system from Applied 
Biosystems/MDS Sciex (Concord, Ontario, Canada) coupled to an Agilent 1100 HPLC 
system (Agilent Technologies, Palo Alto, USA). Prior to the analysis, 50µL of 1µg/mL 
Glipizide was added as the internal standard to 50µL of the buffer sample. Extraction 
was carried out using acetonitrile followed by vortex mixing, centrifugation for 
5min at 15 000g, concentration using a centrifugal vaporizer CVE-200D (EYELA, 
Tokyo, Japan) and dilution in the mobile phase before the injection of 20µL into the 
LC/MS/MS system for analysis .For the chromatographic conditions, the mobile 
phase comprised 0.1% formic acid in ultra-pure H2O:0.1% formic acid in 
acetonitrile (50:50) and a flow rate of 0.2ml/min. The analytical column was of 
2.0mm ID x 150mm length (Shodex® ODP2 HP-2D) and guard column 2.0mm ID x 
10mm (Shodex® ODP2 HPG-2A). Both were of 5µm particle size with the column 
temperature maintained at 400C. Detection was performed using an electrospray 
source (ESI) in positive ionization mode. Quantification was performed in MS/MS 
mode using the following fragmentation transition m/z of 502.1/466.2 and 
446.0/321.1 for FXD and glipizide respectively. System control and data processing 
was done using Analyst software Version 1.4.2. 
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2.1.4 Data analysis.  
The apparent permeability coefficient (Papp) was calculated as: 
Papp = (dQ/dt)/Co x A    [1] 
where dQ/dt is the rate of appearance of drug in the recipient compartment; A 
represents the membrane surface area of the Caco-2 monolayer (0.33 cm2); and C0 
is the initial drug concentration in the donor compartment.  
The efflux ratio (ER) was obtained as: 
ER = Papp B-A/Papp A-B     [2] 
where Papp B-A  and Papp A-B are the mean Papps obtained for transport in the 
basolateral-to-apical (B-A) direction and the apical-to-basolateral (A-B) direction, 
respectively.  
The DIN was calculated as: 
   DIN = Dosei /Ki     [3] 
where Dosei is the maximum therapeutic dose of the inhibitor, and Ki is the 
inhibition constant. The Ki values were generated from ER195) and calculations  
made using Microsoft Excel software (Seattle, WA, USA). 
All results are expressed as the mean ± the standard error of the mean (SEM) 
(n ≥ 3 for each experiment). Values of p < 0.05 were deemed statistically significant 
using Dunnett’s test.  
 
2.2 PAPER II 
2.2.1 Preparation of Extracts. 
Extracts of the leaves or bark (for MLB) were prepared by decoction using 100g per 
100mL distilled water. Prior to this, they were blended using an Ace homogenizer 
(Nihonseiki Kaisha Ltd., Tokyo, Japan) then decocted in distilled water for 30 min at 
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40˚C before being allowed to steep for 4-6 hrs. This was followed by filtration with 
Advantec No. 2 qualitative filter paper (Toyo Roshi Kaisha Ltd, Tokyo, Japan) before 
being concentrated by evaporation at 40˚C in vacuo using an Eyela CVE-200D 
centrifugal vaporizer (Tokyo Rikakikai Co. Ltd., Tokyo, Japan). They were stored at 
4˚C until use. The final concentration of the respective phytomedicines used in the 
experiments ranged from 0.02mg/mL to 20mg/mL of the dried extract dissolved in 
distilled water. The respective extraction yield obtained for each herbal was 5.89, 
8.24, 4.0, 4.92, 7.39 and 3.83% for LG, MLB, ML, CP, VA and NL respectively. 
 
2.2.2 Cell culture.  
Caco-2 cells (passage number 20 - 61) were routinely cultured at 37°C, 95% relative 
humidity and 5% CO2 atmosphere and maintained in Dulbecco’s modified Eagle’s 
medium (Sigma-Aldrich) containing 10% fetal bovine serum and 1% 
antibiotic-antimycotic from Gibco Invitrogen Corp (Grand Island, NY, USA). The 
culture medium was changed every 2-3 days. On reaching an acceptable confluency 
of 80-90%, the cells were detached from the culture flask by introducing a 0.05% 
trypsin-0.02%EDTA solution. Cells were used 16 - 24 days post seeding in order to 
obtain differentiated monolayers and an expected higher expression of transport 
proteins. Cells were seeded at 1x105 cells/cm2 on Transwell membrane inserts 
(Corning, NY, USA) and placed in Transwell 24 well clusters (6.5mm membrane 
diameter, 0.4µm pore size, 0.33cm2 surface area) pre-coated with collagen. 
Monolayer integrity of the permeable membrane was assessed by the 
transepithelial electrical resistance (TEER) of the monolayers using a Millicell ERS-2 
(Millipore, Billerica, MA, USA). Only cell monolayers with TEER values above 
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250Ωcm2 were used in the transport experiments. 
 
2.2.3 Transport study.  
Transport experiments were conducted in Hank’s balanced salt solution (HBSS) 
buffered with 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (pH 7.4) 
at 37°C. Prior to the experiments, the monolayers were washed twice with the 
transport medium and pre-incubated for 20 min. To examine the effects of the 
extracts on P-gp mediated transport, the extracts (0.02, 0.2, 1, 2, 5, 10, and 20 
mg/mL) were added to both apical and basolateral sides at equal concentrations. 
VER 100 µM was used as a positive inhibitor control. The apical chamber had a final 
volume of 100 µL while the basolateral chamber contained 600 µL. The experiments 
were initiated by the addition of 3H-DIG to the donor compartment (apical chamber 
for A-B transport studies and basolateral chamber for B-A transport studies, 
respectively). 50 µL samples were taken from the either the donor or receiving 
compartment at time intervals of 30, 60, 90 and 120min; the removed volume was 
replaced with a corresponding volume of pre-warmed drug-free HBSS solution at 
37°C.  
 
2.2.4 Cellular viability study.  
The cytotoxic effects of the phytomedicines under investigation was examined using 
the colorimetric MTT [3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide] assay. Caco-2 cells were seeded on standard 96-well microplates at a 
density of 1 x 104 cells/well. They were subsequently treated with VER, DIG and the 
extracts (0.02, 0.2, 1, 2, 5, 10, and 20 mg/mL) for 120 minutes with HBSS as the 
control. The cells were then incubated with MTT in phenol red-free Dulbecco’s 
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modified eagle’s medium (Sigma-Aldrich) at 37°C for 4 hours. DMSO was introduced 
to solubilize the cells and incubated for 10 minutes at 37°C. Absorbance was read at 
570nm (reference at 630nm) using a Multiskan JX microplate reader (Thermo 
Scientific, Tokyo, Japan). Cell viability was calculated as a percentage of HBSS 
control. 
 
2.2.5 Quantification of DIG transport.  
In order to determine the amount of [3H] – DIG transported, 50 µL sample was 
mixed with 2mL of Clear-sol I scintillation cocktail (Nacalai Tesque, Kyoto, Japan) 
and the radioactivity was measured with a LSC-6100 liquid scintillation counter 
(Aloka, Tokyo, Japan) 
 
2.2.6 Data analysis.  
The apparent permeability coefficient (Papp) used as an expression of the 
absorption rate constant was calculated as 
Papp= (dQ/dt) / (Co x A)      
dQ/dt represents the rate of appearance of drug in the receiver chamber, A 
represents the membrane surface area of Caco-2 monolayer (0.33cm2), and C0 is 
the initial drug concentration on the donor side.  
In order to compute the efflux ratio (ER), the bidirectional Papp of [3H] – DIG in the 
presence and absence of the extracts and VER were collated. ER was calculated as 
ER = Papp B-A  / Papp A-B     
With Papp B-A  and Papp A-B as the mean permeability coefficient obtained for the 
basolateral-to-apical direction and apical-to-basolateral direction respectively. 
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2.2.7 Statistical analysis.  
All data are expressed as mean ± standard error of mean (SEM) of at least 3 
replicate determinations. Values of *, p < 0.05; **, p < 0.01; *** p < 0.001 were 
considered to be statistically significant using two-tailed t-test and Dunnett’s 
analysis.  
 
2.3 PAPER III 
2.3.1 Herbs.  
The aqueous herbal extracts investigated in this study were from bitter leaf (VA), 
pawpaw leaves (CP), and a species of mistletoe leaves (ML). The plant parts were 
collected from their natural habitat in various locations near Jos, Nigeria, and were 
dried in the shade for several days at room temperature. The identity of the plants 
was confirmed at the Forestry Research Institute of Nigeria, Ibadan, where voucher 
specimens were deposited. Leaves were blended using an Ace homogenizer 
(Nipponseiki Co. Ltd., Tokyo, Japan) and extracts were prepared by decoction for 30 
min at 40°C using 100 g of leaves per 100 ml distilled water before being allowed to 
steep for 6 h. This was followed by filtration with Advantec No. 2 qualitative filter 
paper (Toyo Roshi Kaisha Ltd, Tokyo, Japan) before extracts were concentrated by 
evaporation at 40°C in vacuo using an Eyela CVE-200D centrifugal vaporizer (Tokyo 
Rikakikai Co. Ltd., Tokyo, Japan). Samples were stored at 4°C until use.  
 
2.3.2 Animals.  
Healthy male Sprague Dawley (SD) rats (220–300 g) obtained from Japan SLC Inc. 
(Shizuoka, Japan) were maintained in the housing facility in a 
temperature-controlled environment with a 12 h light/12 h dark cycle and 
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received a standard diet with water. The animals were housed in this facility for at 
least one week before experiments were initiated to ensure proper acclimatization. 
Prior to each experiment, the rats were fasted overnight but had free access to 
water and were randomly assigned to different groups. The study was approved by 
the Chiba University Animal Ethics Committee. The research adhered to the 
“Principles of Laboratory Animal Care” 194).  
 
2.3.3 Transport studies across the rat ileum in Ussing chambers.  
After anaesthetization with diethyl ether and laparotomy through a midline 
abdominal incision, the small intestine was immediately excised and immersed in 
ice-cold, freshly prepared standard Kreb Ringers bicarbonate buffer, KRBB [115 
mM NaCl, 25 mM NaHCO3, 2.4 mM K2HPO4, 1.2 mM CaCl2, 1.2 mM MgCl2, 0.4 mM 
KH2PO4 maintained at pH 7.4] bubbled with carbogen (95% O2, 5% CO2). Ileum 
that had been cut 25 cm proximally from the caecum was used. The tissue was 
rinsed with ice-cold standard KRBB to remove the luminal contents and cut into 
1.7 cm long segments, excluding visible Peyer’s patches. The ileum segments were 
opened along the mesenteric border and stretched onto pins on one half of the 
chamber with an exposed tissue area of 0.64 cm2 placed between two Navicyte 
side-by-side chambers (Harvard Apparatus, Holliston, MA) clamped together. Each 
compartment was filled with 5 ml of KRBB buffer supplemented with 10 mM 
D-glucose or 10 mM mannitol on the serosal and mucosal side of the ileal tissue, 
respectively. The tissue was kept at 37°C during the experiments using a 
circulating water bath attached to a heat block. The incubation buffer inside the 
diffusion chambers was oxygenated and circulated by bubbling with carbogen 
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through a gas manifold. After pre-incubation for 40–50 min with the test inhibitor 
agent diluted in KRBB (final concentrations of 200 µM VER; 20 µM CysA; 10 mg/ml 
of each of the herbal extracts), digoxin was added to a final concentration of 10 μM 
(7 nmol of 3H-digoxin/mol of unlabeled digoxin) to the incubation buffer on the 
mucosal side of the chamber. At time intervals of 15, 30, 60, 90, 105, and 120 min 
after the introduction of digoxin, 1 ml aliquots were withdrawn from the serosal 
chamber and were replaced with the appropriate volume of drug-free buffer to 
maintain a constant volume in the chamber. The amount of permeated digoxin was 
assayed using liquid scintillation counting. The amount of 3H-digoxin transported 
was quantified by mixing the 1 ml sample with 2 ml of Clear-sol I scintillation 
cocktail (Nacalai Tesque, Kyoto, Japan) and radioactivity was measured with a 
LSC-6100 liquid scintillation counter (Aloka, Tokyo, Japan). Ileal tissue integrity and 
viability were observed throughout each study by measuring the transepithelial 
electrical resistance (TEER), using a Millicell ERS-2 (Millipore, Billerica, MA). 
 
2.3.4 In vivo pharmacokinetic studies. 
The rats were randomly assigned into five different groups each containing 5–9 rats. 
One group served as the control and these rats were pre-treated with 0.5 % sodium 
carboxymethylcellulose 2 h before receiving 25.6 µmol/kg digoxin by oral gavage 
(0.17 µmol of 3H-digoxin/mol of unlabeled digoxin) in 0.2 ml of vehicle. For the 
groups pre-treated with herbal extracts, the rats were administered a dose of 90 
mg/kg (suspended in the vehicle) by oral gavage 2 h prior to receiving digoxin. The 
VER control group received 25 mg/kg p.o VER 2 h before receiving digoxin. A 
heating lamp was used to maintain blood temperature, increase circulation, and 
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improve blood collection. Blood samples were taken from the saphenous vein by 
venipuncture and transferred into heparinized tubes at 15, 30, 45, 60, 90, 120, and 
180 min after oral administration of 25.6 µmol/kg digoxin. Blood samples were 
stored at –20°C before 3H activity was quantified using liquid scintillation after 
mixing blood with the scintillation cocktail as described above. The rats were 
sacrificed with an anesthetic overdose on completion of each experiment. 
 
2.3.5 Data treatment and statistical analysis.  
The apparent permeability coefficient (Papp) was calculated as: Papp = (dQ/dt) / (C 
x A). dQ/dt represents the rate of appearance of digoxin in the receiver chamber, A 
represents the exposed membrane surface area of the ileal tissue (0.64 cm2), and C 
is the initial digoxin concentration on the donor side.  
All data are expressed as mean ± standard error of mean (SEM) of at least three 
replicates for Ussing experiments and 5–9 replicates for in vivo experiments. 
Statistical significance was assessed using GraphPad Prism version 5 (GraphPad 
Software, La Jolla, CA) considering values of *p<0.05, **p<0.01, ***p<0.001 to be 
significant using one-way analysis of variance with Dunnett's post-test for multiple 
comparisons. 
A series of pharmacokinetic parameters were determined based on the individual 
plasma concentration-time data. Peak digoxin concentrations (Cmax; in ng/ml) were 
taken directly from the data. The area under the plasma concentration-time curve 
(AUC; in ng/ml/h) of digoxin for 0–3 h was calculated by the linear trapezoidal rule 
and extrapolated to infinity using standard procedures to obtain AUC0-∞. The 
elimination rate constant (kel; h-1) was estimated by log-linear regression of the 
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terminal portion of the plasma concentration–time curve and elimination half-life 
(T1/2; h) was calculated as 0.693/kel.  
 
2.4 PAPER IV 
2.4.1 Incubations with Human Liver/Intestinal Microsomes (HLM/HIM). Several 
preliminary studies were carried out to determine incubation conditions that 
maximized artemisinin metabolism, ensured linearity with respect to microsomal 
protein concentration and incubation time as well as confirmed suitability of the 
extraction process. Briefly, a typical protein mixture (1ml/reaction) contained 0.1 
mg protein/mL HLM/HIM, artemisinin, the NADPH-generating system (MgCl2 5 
mM, G6P 5 mM and G6PDH 1 IU/mL in reaction buffer) and 100 mM potassium 
phosphate buffer containing 100 mM EDTA (pH 7.4). Each sample was 
pre-incubated at 37 °C for 5 min. The reaction was initiated by the addition of 
NADP+ (0.5 mM) then incubated at 37 °C for 2 or 5min for HLM and HIM 
respectively. After incubation, 530 µL of a mixture of ice-cold 1M NaHCO3 and 
100mM Na2CO3 (to pH 11) was added to each sample on ice to stop the reaction 
followed by vortex mixing. 170 µL of 10 µg/ml artemether was introduced as the 
internal standard. Extraction was carried out using ethyl acetate followed by shaking 
on a horizontal shaker for 20 min. The samples were then centrifuged for 20 min at 
5000rpm at room temperature. The organic layer was dried under a gentle stream of 
N2 gas. Each sample was diluted to 100uL of the mobile phase before injection of 20 
μL in the LC/MS/MS system. 
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2.4.2 Investigation of CYP3A4 contribution to the metabolism of 
artemisinin.  
To assess the contribution of CYP3A4 to the metabolism of ASN, incubation studies 
involving chemical inhibition (using KTZ) was carried out. Briefly, for the chemical 
inhibition studies, KTZ was utilized as a chemical inhibitor on CYP3A4-mediated 
metabolism of artemisinin. Artemisinin (50 µM) was incubated with 0.1 mg of 
microsomal protein/mL (HIM/HLM) to a final volume of 1000 µL. The mixtures 
containing enzymes, potassium phosphate buffer (100 mM, pH 7.4), MgCl2 (5 mM), 
G6P (5 mM), G6PDH (1U/mL) and artemisinin with or without KTZ (0.1 and 1 µM) 
were pre-incubated at 37 oC for 5 minutes. The reaction was initiated by the 
addition of NADP+ (final concentration: 0.5 mM) and incubated at 37 oC for 2 or 5 
min. After incubation, the reaction was terminated as above and further treated for 
incubations with human liver/intestinal microsomes. In order to determine the 
degree of inhibition, metabolism of artemisinin in the absence of KTZ (control) was 
compared with that in the presence of KTZ and expressed as percentage remaining 
with respect to control. The values of % of control were plotted in comparison with 
the KTZ concentrations. 
 
2.4.3 Inhibition Studies 
In vitro inhibition of the biotransformation of artemisinin was investigated using 
SQV, RTV, NLF and NVP in HLMs. All incubations were conducted under linear rate 
conditions. ASN (50 µM) was incubated with 0.1 mg of microsomal protein/mL 
HLM to a final volume of 1000 µL. The mixtures containing enzymes, potassium 
phosphate buffer (100 mM, pH 7.4), MgCl2 (5 mM), G6P (5 mM), G6PDH (1U/mL) 
and artemisinin with or without RTV (0, 0.1, 1, 10, 20, 50 and 100 µM), NLF (0.1, 1, 
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5, 10, 30, 50 and 100 µM), NVP (0.1, 1. 10, 30, 100 and 300 µM) or SQV (0, 0.3, 1, 3, 
10, 30 and 100 µM) were pre-incubated at 37 oC for 5 minutes. The reaction was 
initiated by the addition of NADP+ (final concentration; 0.5 mM) and incubated at 
37 oC for 2 min. After incubation, the reaction was terminated and further treated 
following the same procedure as that described for the incubations with human 
liver/intestinal microsomes. 
 
2.4.4 Quantification of Artemisinin by LC/MS/MS analysis. 
In order to determine the amount of artemisinin remaining after the metabolism 
studies, samples were analyzed on a hybrid triple quadrupole linear ion trap 
(QTRAP) 4000 LC/MS/MS system from Applied Biosystems /MDS Sciex (Concord, 
Ontario, Canada) coupled to an Agilent 1100 HPLC system (Agilent Technologies, 
Palo Alto, USA). Each sample was diluted to 100uL of the mobile phase before the 
injection of 20 μL in the LC/MS/MS system. For the chromatographic conditions, 
the mobile phase comprised CH3CN: CH3COONH4 +0.1% HCOOH (85:15) at a flow 
rate of 0.2ml/min. The analytical column was of 2.0mm ID x 150mm length 
(Shodex® ODP2 HP-2D, Showa Denko KK, Japan) and guard column 2.0mm ID x 
10mm (Shodex® ODP2 HPG-2A, Showa Denko KK, Japan). Both were of 5µm particle 
size with the column temperature maintained at 40 0C. Detection was performed 
using an electrospray source (ESI) in positive ionization mode. Quantification was 
performed in MS/MS mode using the following fragmentation transition m/z of 
283.2/151.2 and 316.3/163.2 for artemisinin and artemether respectively. System 
control and data processing was done using Analyst software Version 1.4.2(Applied 
Biosystems, Foster City, CA, USA). 
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2.4.5 Data Analysis and Statistics.  
All data is expressed as mean ± standard error of mean (SEM). Kinetic parameters 
(apparent Km and Vmax) were calculated by nonlinear regression by directly fitting 
the data into Michaelis-Menten equation and expressed as mean ± SEM. Data 
analysis was carried out using GraphPad Prism Version 5 (GraphPad Software Inc., 
La Jolla, CA, USA). Statistical significance was analyzed using two-tailed Students 
t-test as well as ANOVA followed by Dunnetts test. Values of *p < 0.05 were 
considered to be statistically significant. 
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3. RESULTS 
3.1 PAPER I 
3.1.1 Transport and inhibition of Rho-123 across Caco-2 cell monolayers.  
The B-A transport of Rho-123 (5 µM), a typical P-gp substrate, was first investigated 
at 120 min in the presence or absence of drugs (Figure 10) VER (100 µM) and QD 
(1 µM) were employed as positive controls for P-gp inhibition and significantly 
decreased Rho-123 transport across the Caco-2 cell monolayer. The effect of seven 
antimalarials (ART, ASN, ATM, ADQ, CQ, LUM, and SDX, each employed at a 
concentration of 1 mM) on Rho-123 transport was next examined. Among these 
antimalarials, ART and ADQ showed the most significant inhibitory effects. LUM also 
exhibited some inhibition of Rho-123 transport, although its actions were less 
pronounced than those of ART and ADQ. ART, ADQ, and LUM were therefore used 
in the subsequent experiments. 
 
 
Figure 10. Preliminary screening for the inhibition of P-glycoprotein  
Each column represents the mean ± the standard error of the mean (SEM) (n ≥ 3). 
*Significant difference, p < 0.05 versus control (transport in the absence of drugs). 
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3.1.2 Transepithelial transport of DIG across Caco-2 cell monolayers.  
The bi-directional transport of [3H]-DIG was then examined. In the body, DIG is 
primarily transported in the B-A direction across the intestinal barrier epithelium 
by P-gp. Figure 11A illustrates the basic transport characteristics of DIG across the 
model Caco-2 cell monolayer in the presence or absence of VER (100 µM), the 
positive inhibition control. As shown in the figure, transport rate of DIG in the B-A 
direction was greater than that in the A-B direction by over ten-fold. These data are 
consistent with high expression of P-gp by the Caco-2 cell monolayer and with 
P-gp-mediated transport as the predominant means of DIG conveyance. The 
introduction of VER significantly decreased transport of DIG in the B-A direction (p 
< 0.05), and only slightly increased transport in the A-B direction. 
3.1.3 Effect of antimalarials on transepithelial transport of DIG and FXD.  
The effect of LUM, ADQ, and ART (100 µM and 1 mM) on P-gp-mediated DIG 
transport was next investigated. Figure 11B shows the bi-directional transport of 
DIG across the Caco-2 cell monolayer in the presence or absence of LUM (100 µM 
and 1 mM). In the B-A direction, significant 33 and 38% decreases in the transport 
rate of DIG were observed for LUM at concentrations of 100 µM and 1 mM, 
respectively, which is suggestive of P-gp inhibition (p < 0.05). However, transport 
was only minimally affected by LUM in the A-B direction. Figure 11C demonstrates 
that the transport of DIG in the B-A direction was also significantly impaired by 
ADQ. B-A transport of DIG was reduced by 38 and 77% in the presence of ADQ at 
concentrations of 100 µM and 1 mM, respectively (p < 0.05). As for LUM, this result 
is indicative of P-gp inhibition. Here, ADQ (1 mM) showed more potent inhibition 
than the positive inhibition control, VER (100 µM). In the A-B direction, ADQ (1 
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mM) significantly stimulated DIG transport by 25%. An increase in the A-B 
transport of DIG was also seen with the co-administration of VER (100 µM). ART 
was the last antimalarial to be investigated. Figure 11D shows significant decreases 
in DIG transport in the B-A direction by 36 and 56% in the presence of ART at 
concentrations of 100 µM and 1 mM, respectively (p < 0.05). No significant impact 
was observed on A-B transport. Therefore, LUM, ADQ, and ART all inhibited B-A 
transport of DIG, with 1 mM ADQ exhibiting the most potent inhibition. These 
results confirm the P-gp inhibitory effect of the antimalarials that was initially 
observed in the Rho-123 transport assay. Table 4 shows the Papps of DIG in the 
presence or absence of LUM, ADQ, ART, and VER in the A-B and B-A directions, 
calculated based on the data shown in Figure 11 (A-D).  DIG alone showed an ER of 
10.8, further confirming it as a P-gp substrate. Significant effects were observed for 
ART, ADQ, LUM (1mM) and VER in the B-A transport of DIG while ADQ (1 mM) and 
VER significantly increased its A-B transport. 
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Figure 11. Digoxin (DIG) and antimalarial drug kinetics.  
DIG transport across Caco-2 cell monolayer was examined as a function of time. 
Apical-to-basolateral (A-B) transport and basolateral-to-apical (B-A) transport of 
DIG was investigated in the presence or absence of A, Verapamil B, lumefantrine 
(LUM, 100 µM and 1 mM); C, amodiaquin (ADQ, 100 µM and 1 mM); and D, 
artesunate (ART, 100 µM and 1 mM). Each data point represents the mean ± SEM of 
at least four determinations. Solid lines represent basolateral-to-apical (B-A) 
transport, and dashed lines represent apical-to-basolateral (A-B) transport. 
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Table 4. Permeability coefficient (Papp) and efflux ratio (ER) of digoxin 
 
 Papp*10-6 cm/s Papp *10-6 cm/s ER 
 A-B B-A  
DIG alone 3.14 ± 0.04 33.8 ± 1.63 10.8 
DIG + 100 µM ART 2.00 ± 0.22 20.98 ± 0.24* 10.5 
DIG + 1 mM ART 2.84 ± 0.22 14.85 ± 0.41* 5.2 
DIG + 100 µM ADQ 2.15 ± 0.07 20.35 ± 0.81* 9.5 
DIG + 1 mM ADQ 4.03 ± 0.06* 7.60 ± 0.55* 1.9 
DIG + 100 µM LUM 3.01 ± 0.08 22.81 ± 1.39 7.6 
DIG + 1 mM LUM 2.74 ± 0.06 20.67 ± 0.76* 7.5 
DIG + 100 µM VER 4.36 ± 0.13* 17.30 ± 0.50* 4.0 
 
The apparent permeability coefficient (Papp) and efflux ratio (ER) values of digoxin 
(DIG) in combination with artesunate (ART), amodiaquin (ADQ), and lumefantrine 
(LUM) at the indicated concentrations in the apical-to-basolateral (A-B) and 
basolateral-to-apical (B-A) direction across a Caco-2 cell monolayer. *Significant 
difference, p < 0.05 versus control. 
 
 
The effect of 100µM and 1000µM ART, ADQ and LUM on FXD transport in Caco-2 
cell monolayers was examined. Figure 12A shows FXD transport with or without 
the introduction of 100µM VER, the positive inhibition control. VER reduced FXD 
transport (B-A) by 55% and increased A-B transport by 36% as expected for the 
interaction between P-gp substrates and inhibitors. FXD transport in the presence 
and absence of 100µM and 1000µM LUM is represented in Figure 12B. However, 
there was non-significant increase of 2% in B-A direction by 1000µM LUM 
suggestive of non-inhibitory effect on P-gp of this amount. However in the A-B 
direction, increases of 10% and 13% for 100µM and 1000µM were observed. 
Figure 12C shows the bidirectional transport of FXD in the presence or absence of 
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100µM and 1000µM ADQ. In the B-A direction, 100µM ADQ reduced FXD transport 
by 39% while 1000µM ADQ increased its transport by 104%. Increase of 15% and 
5% were observed for 100µM and 1000µM ADQ respectively in the A-B direction. 
In Figure 12D, the B-A transport of FXD in the presence of ART decreased by 26 % 
of control for 100µM. However at 1000µM, there was an 80% significant increase in 
FXD transport. Transport in the A-B direction showed increases of 17% and 6% for 
100µM and 1000µM ART respectively. From these, VER, the positive control 
showed the most inhibition to FXD transport. 100µM LUM, ART and ADQ also 
showed inhibition to FXD transport. However, all the examined anti-malarials at 
1000µM seemed to increase FXD transport. In the A-B direction, there was an 
increase in FXD transport for all the anti-malarials at both concentrations. This is 
suggestive of the interaction of these anti-malarials with P-gp and possibly other 
transporters (Table 5).  
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Figure 12. Fexofenadine (FXD) and antimalarial drug kinetics. 
FXD transport across Caco-2 cell monolayer was examined as a function of time. 
Apical-to-basolateral (A-B) transport and basolateral-to-apical (B-A) transport of 
FXD was investigated in the presence or absence of A, Verapamil B, lumefantrine 
(LUM, 100 µM and 1 mM); C, amodiaquin (ADQ, 100 µM and 1 mM); and D, 
artesunate (ART, 100 µM and 1 mM). Each data point represents the mean ± SEM of 
at least four determinations. Solid lines represent basolateral-to-apical (B-A) 
transport, and dashed lines represent apical-to-basolateral (A-B) transport. 
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Table 5. Permeability coefficient and efflux ratio on co-administration with 
FXD 
 
 
P
app
*10
-6
cm/s 
(A-B) 
P
app
 *10
-6
cm/s 
(B-A) 
Efflux ratio 
FXD alone 3.14 ± 0.27 21.13 ±  2.47 6.7 
+100µM ART 3.66 ± 0.42 16.42 ± 1.33* 4.5 
+1000µM ART 3.36 ± 0.39 36.12 ± 1.88 10.7 
+100µM ADQ 3.57 ± 0.13 12.95 ± 0.82* 3.6 
+1000µM ADQ 3.28  ± 0.16 40.81 ± 1.13 12.4 
+100µM LUM 3.43 ± 0.11 23.09 ± 3.33 6.7 
+1000µM LUM 3.54 ± 0.24 20.27 ± 3.17 5.7 
+100µM VER 4.26 ± 0.20* 8.94 ± 1.81* 2.1 
The apparent permeability coefficient (Papp) and efflux ratio (ER) values of 
fexofenadine (FXD) in combination with artesunate (ART), amodiaquin (ADQ), and 
lumefantrine (LUM) at the indicated concentrations in the apical-to-basolateral 
(A-B) and basolateral-to-apical (B-A) direction across a Caco-2 cell monolayer. 
*Significant difference, p < 0.05 versus control. 
 
 
 
For FXD transport, there was a decrease in efflux ratio for the anti-malarials and 
VER except for 1000µM ART and 1000µM ADQ. The changes in the efflux ratio of 
DIG and FXD are illustrated in Figure 13. 
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Figure 13. Efflux ratio values of digoxin and fexofenadine  
The efflux ratio values of DIG and FXD alone and on co-administration with the 
antimalarials; lumefantrine (LUM), artesunate (ART) and amodiaquin (ADQ). 
 
Subsequently, the DINs for ADQ, ART, and LUM on co-administration with DIG were 
calculated. As indicated in Figure 14, The DINs for ADQ, ART, and LUM were 46.7, 
12.6, and 0.7, respectively, indicating the greatest risk of DDIs for ADQ. 
 
 
Figure 14. Drug interaction Numbers with Digoxin 
The computed Drug Interaction Numbers (DIN) of the antimalarials on 
co-administration with Digoxin 
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3.2 PAPER II 
To examine the transport and inhibition of [3H] – DIG in Caco-2 cell monolayers, the 
Caco-2 cell monolayer system was validated by examining the bi-directional 
transport of [3H] – DIG, a typical P-gp substrate. As shown in Figure 15, transport of 
DIG in the B-A direction was much greater than transport in the A-B direction by 
about seven-fold.  This data confirms good expression of P-gp in the Caco-2 cell 
monolayers utilized as well as predominant P-gp mediated transport. P-gp 
inhibition was investigated by assessing bidirectional transport in the absence or 
presence of 100 µM VER (a typical P-gp inhibitor). In the presence of VER, there 
was very significant decrease (73%) in the mean B-A transport while there was 
significant increase (46%) in the A-B transport further confirming the P-gp 
inhibitory effect of VER. Transepithelial bidirectional transport of DIG was 
time-dependent. B-A transport studies were initially carried out for seven 
phytomedicines extracts at concentration range of 0.02 - 20 mg/mL and the extent 
of inhibition to P-gp mediated DIG transport was assessed. As illustrated in Figure 
16, statistically significant inhibition was observed at concentrations of 1 - 20 
mg/mL for VA and CP (with inhibition to DIG transport of 59 - 73% and 31 - 58% 
respectively) as well as 0.02 - 20 mg/mL for ML (with inhibition to DIG transport of 
45 - 91%). CUR also showed statistically significant difference at 0.02 - 2 mg/mL. 
Subsequently, the A-B transport of CP, VA, and ML was further investigated. The 
effect of extracts of ML, CP and VA on the bidirectional transport of DIG is illustrated 
in Figure 17 (A and B). Increases were observed in DIG mediated A-B P-gp 
transport. Here, typical P-gp inhibitor; VER also enhanced the apical-to-basal 
transport of DIG in Caco-2 cells, suggesting that P-gp mediates the efflux transport 
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of DIG in the apical membranes of Caco-2 cells. In addition, as illustrated in Table 6, 
the ratio of B-A transport to A-B transport of CP, VA, ML  and the inhibition control 
VER strongly suppressed the net secretory transport of DIG as evidenced by the 
decrease in ER when compared to the control (DIG). 
 
 
 
Figure 15.  Digoxin transport kinetics  
The bi-directional transport DIG in the absence and presence of 100 µM verapamil, 
VER across Caco-2 cell monolayers was determined against time. DIG transport in 
the basolateral to apical side was about seven-fold higher than transport in the 
apical-to-basolateral . Solid lines represent passage in the absence of verapamil, 
dashed lines represent  passage in the presence of verapamil. Each data point 
represents the mean of 4-7 replicate assays (±SEM). 
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Figure 16. Basolateral-to-apical transport on co-administration with Digoxin 
(Dig)   
Basolateral-to-apical transport of Digoxin (Solid red line) across Caco-2 cell 
monolayers expressed as a percentage of DIG control in the presence of 0.02mg/mL 
– 20 mg/mL of the respective phytomedicines; CUR, Curcuma longa; NL, 
Azadiractha indica; LG, Cymbopogon citratus; MLB, Morinda lucida;  VA,Vernonia 
amygdalina; CP,Carica papaya and ML, Mistletoe leaves. All data are expressed as 
mean ±SEM of 3-4 replicates. Values of * p < 0.05, ** p < 0.01 and *** p < 0.001 
were considered to be statistically significantly different from DIG control 
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Figure 17. Bidirectional transport on co-administration with Digoxin (Dig) 
Bidirectional transport A) Secretory transport B) Absorptive transport of DIG; 
Digoxin across Caco-2 cell monolayers in the presence of 0.02mg/mL – 20 mg/mL 
of ML; Mistletoe leaves,  CP; Carica papaya, VA, Vernonia amygdalina – the 
phytomedicines that initially showed significant inhibition to basolateral-to-apical 
transport. [A], basolateral-to-apical passage; (B), apical-to-basolateral passage. All 
data are expressed as mean ± SEM of 3-4 replicates. 
75 
 
Table 6. Permeability coefficient and efflux ratio on co-administration with 
digoxin   
 
Apparent permeability coefficient (Papp) and efflux ratio (ER) of digoxin (DIG) in 
combination with leaf extracts of Tapinanthus sessilifolius (ML), Carica papaya (CP), 
Vernonia amygdalina (VA), and Verapamil (VER) at the indicated concentrations in 
the apical-to-basolateral (A-B) and basolateral-to-apical (B-A) direction across a 
Caco-2 cell monolayer. 
Significant difference *p < 0.05, ** p < 0.01, *** p <0.001 versus DIG control. 
 
In order to confirm that the observed inhibitory effects of the extracts were not due 
to their cytotoxicity, in vitro cytotoxicity studies were carried out with HBSS as the 
 Papp*10-6 cm/s 
ER 
Test agent A-B B-A 
DIG alone 3.60  ± 0.02 25.01 ± 1.50 6.9 
DIG + ML 1 mg/mL 3.03  ± 0.06 10.07  ± 0.35** 3.3 
DIG + ML 2 mg/mL 3.69  ± 0.36 8.75 ± 0.16** 2.4 
DIG + ML 5 mg/mL 3.61  ± 0.69 5.72  ± 0.43*** 1.6 
DIG + ML 10 mg/mL 2.69  ± 0.11 3.49  ± 0.13*** 1.3 
DIG + ML 20 mg/mL 2.61  ± 0.39 2.90  ± 0.14*** 1.1 
DIG + CP 1 mg/mL 3.96  ± 0.22 15.69  ± 0.38* 4.0 
DIG + CP 2 mg/mL 4.43  ± 0.09* 18.01  ± 0.71* 4.1 
DIG + CP 5 mg/mL 4.33  ± 0.05* 17.74 ± 0.68* 4.1 
DIG + CP 10 mg/mL 4.11  ± 0.4 12.35  ± 0.58** 3.0 
DIG + CP 20 mg/mL 4.47  ± 0.03* 11.64  ± 0.41** 2.6 
DIG + VA 1 mg/mL 4.96  ± 0.29** 9.98   ± 0.59** 2.0 
DIG + VA 2 mg/mL 5.15  ± 0.89* 11.07  ± 0.71** 2.1 
DIG + VA 5 mg/mL 5.18  ± 0.41** 10.51  ± 1.61** 2.0 
DIG + VA 10 mg/mL 3.72  ± 0.16 7.35  ± 0.68** 2.0 
DIG + VA 20 mg/mL 4.19  ± 0.08* 10.72  ± 0.83** 2.6 
DIG + 100 µM VER 6.69  ± 0.25*** 7.07  ± 0.99*** 1.1 
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control medium. The MTT test was conducted to assess the 
concentration-dependent cytotoxic effects of ML, CP, VA, VER and 10 µM DIG. Figure 
18 shows a statistically significant increase in cell viability for 5 and 10 mg/mL ML 
and 1 and 5 mg/mL VA when compared with the HBSS control. No cytotoxic 
reduction in cell viability was significant. DIG and VER did not significantly alter cell 
viability (data not shown). From this data, none of the phytomedicines was found to 
be cytotoxic to the cells at the concentrations examined. 
 
 
 
 
 
Figure 18. Cell viability of the investigated herbal extracts 
Cell viability (percentage of HBSS control) for 0.02mg/mL -20mg/mL of the 
phytomedicines (ML, Mistletoe leaves ;CP,Carica papaya; VA,Vernonia amygdalina). 
All data are expressed as mean ± SEM of 3-4 replicates. Values of * p < 0.05 and ** p 
< 0.01 were considered to be statistically significantly different from the HBSS 
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control  
 
3.3 PAPER III 
3.3.1 Tissue integrity and viability.  
The electrophysiological parameter TEER of the ileal segments was monitored 
throughout the experiments to assess the maintenance of tissue viability and 
integrity. The values were measured before and during the course of each 
permeation experiment. The TEER ranged from 55 to 75 Ω.cm2 prior to the 
introduction of the test agents. Any tissue segment that showed a deviation of 
±15 % from this range was excluded from the experiments. The TEER values were 
stable with no significant variation following introduction of the test agents. Tissue 
viability in the Ussing chamber decreases over time; therefore, sampling times did 
not exceed 120 min. 
 
3.3.2 Mucosal-to-serosal transport across the rat ileal tissue.  
The time-course of the percentage of digoxin transported in the absorptive 
direction (mucosal-to-serosal) in the presence or absence of the test agents and the 
control inhibitors (VER and CysA) is illustrated in Figure 19. Digoxin was used as 
the model P-gp substrate as it is clinically relevant. The mean apparent permeability 
values obtained 120 min after the introduction of digoxin are shown in Figure 20 in 
comparison to the control (digoxin alone). The increase in Papp was highest 
following treatment with the positive control inhibitor, VER, where Papp was 
significantly 56 % higher than in the control. In comparison to the control, Papp 
was significantly higher, by 54.5, 43.3, 16.2 and 7.8 % following treatment with CP, 
VA, CysA, and ML, respectively. 
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Figure 19.  Time course of the absorptive transport of digoxin (Dig)  
Time course of the percentage of digoxin (Dig) transported in the absorptive 
(mucosal-to-serosal) direction with or without verapamil (VER), cyclosporin A 
(CysA) and the herbal extracts; Vernonia amygdalina (VA), Carica papaya (CP) and 
Tapinanthus sessilifolius (ML). The intestinal permeability of the herbal extracts as 
well as the inhibitor controls was determined using the rat ileum segment in an ex 
vivo assay utilizing the Ussing chamber.  Each value represents mean ± SEM (n = 
4). 
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Figure 20. Mean apparent permeability coefﬁcients for digoxin (Dig) 
Mean apparent permeability coefﬁcients obtained for digoxin (Dig) in the 
absorptive direction (mucosal-to-serosal) at 120 min in the presence and absence 
of verapamil (VER), cyclosporin A (CysA), extracts of Vernonia amygdalina (VA), 
Carica papaya (CP) and Tapinanthus sessilifolius (ML). Each value represents mean 
± SEM (n = 4). Significant differences of *, p < 0.05; **, p < 0.01; *** p < 0.001 were 
determined using one-way analysis of variance with Dunnett's post-test for multiple 
comparisons. 
 
 
3.3.3 In vivo pharmacokinetic study.  
To determine whether the inhibition of P-gp observed in vitro (in Caco-2 cells) and 
ex vivo (in Ussing chambers) also occurs in vivo, pharmacokinetic parameters of 
digoxin with or without co-administration of the herbal extracts were determined in 
male SD rats. The mean (±SEM) plasma digoxin concentration versus time profiles 
after a single dose of oral digoxin was administered alone or was co-administered 
with ML, CP, VA, or VER are illustrated in Figure 21 (A-D). The pharmacokinetic 
parameters are summarized in Table 7. 
ML administration non-significantly increased the AUC (0-3) and AUC (0-∞) of digoxin 
by 1.2- and 1.4-fold, respectively, compared to the control group (Figure 21A). Cmax 
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was 1.1-fold higher in the ML-treated group than in the control group. T1/2 
increased from 2.0 h to 2.7 h following ML administration. Figure 21B depicts the 
influence of CP on digoxin pharmacokinetics. Co-administration of CP 
non-significantly increased the AUC (0-3) and AUC (0-∞) of digoxin by 1.1- and 1.3-fold, 
respectively, compared to the control group. Cmax was 1.2-fold higher in the 
CP-treated group than in the control group. T1/2 increased from 2.0 to 2.7 h 
following CP administration. As demonstrated in Figure 21C, the effects of VA on 
digoxin pharmacokinetics were detected within the first hour following digoxin 
administration. Co-administration of VA increased the AUC (0-3) and AUC (0-∞) of 
digoxin by 1.9- and 2.1-fold, respectively, compared to the control group. Cmax was 
1.7-fold higher in the VA-treated group than in the control group. VA administration 
did not significantly affect clearance or T1/2. 
VER inhibits P-gp and thereby reduces digoxin transport. VER was used as a 
positive control in this study. Figure 21D illustrates the impact of VER on the 
pharmacokinetics of digoxin. As expected following administration of a P-gp 
inhibitor, VER significantly increased both the AUC (0-3) and AUC (0-∞) of digoxin by 
1.5-fold compared to the control. VER administration did not significantly affect T1/2, 
although there was a non-significant reduction in the clearance compared to the 
control group. Cmax was significantly higher (1.3-fold) in the VER-treated group than 
in the control group. The absorption rate constant (Ka) increased 1.2-, 1.3-, and 
1.4-fold following administration of ML, CP, and VA, respectively, compared to the 
control group. Therefore, of the herbs studied, VA exerted its inhibitory effect on 
digoxin transport at the shortest time after administration.  
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Figure 21. Plasma concentration-time curves 
Mean plasma concentration-time curves in Sprague Dawley rats after orally 
administered digoxin (25.6umol/kg); closed circles  when co-administered with 
(A) Tapinanthus sessilifolius, ML (B) Carica papaya, CP (C) Vernonia amygdalina, VA 
(D) Verapamil, VER; open circles. The pre-treated groups were orally administered a 
dose of 90mg/kg for ML, CP and VA or 25mg/kg for VER. They were administered 2 
h prior to digoxin dosing. Error bars represent SEM, (n=5-9/group) 
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Table 7. Pharmacokinetic parameters of digoxin  
    
Pharmacokinetic 
parameter 
DIG + ML + CP +VA +VER 
AUC0-3 (ng/ml/h) 10.34 ± 0.71 12.66 ± 1.18 11.88 ± 1.63 20.01 ± 3.66* 15.49 ± 2.27* 
AUC0-∞  (ng/ml/h) 17.69 ± 2.25 24.65 ± 4.65 23.04 ± 3.38  36.53 ± 8.37* 25.78 ± 5.01* 
CL (L/kg/h) 3.66 ± 0.11 2.94 ± 0.08 3.45 ± 0.11 3.64 ± 0.09 3.01 ± 0.03 
Cmax (ng/ml) 6.21 ± 0.3 6.78 ± 0.7 7.28 ± 1.1 10.55 ± 1.9* 8.03 ± 0.9* 
Ka (h-1) 1.24  ± 0.16 1.45 ± 0.23 1.58 ± 0.20 1.68 ± 0.08 1.23 ± 0.10 
T1/2, el(h) 2.04 ± 0.11 2.65 ± 0.08 2.70 ±0.11 1.99 ± 0.11 1.95 ± 0.03 
Pharmacokinetic parameters of digoxin after oral treatment with and without ML, 
CP, VA (90mg/kg) or VER (25mg/kg) in Sprague Dawley rats. (AUC, Area under the 
concentration-time curve; Cmax, peak concentration; Ka, absorption rate constant; 
T1/2, elimination half-life; CL, total clearance). Each value represents the mean ± 
SEM of 5-9 rats. *statistical significant difference compared to the control rats, p < 
0.05 
 
 
3.4 PAPER IV 
3.4.1 Enzyme kinetics of artemisinin metabolism in HLM  
Figure 22 denotes the main metabolic pathway for artemisinin. Artemisinin (10 
-1000µM) was incubated in HLM for 2min at 37oC and the metabolic 
rate-concentration profile is shown in Figure 23. The kinetic parameters Vmax and 
Km were obtained as 9.54 ± 3.52 mmol/min/mg microsomal protein and 922 ± 582 
µM respectively.  
83 
 
 
Figure 22. Scheme for the oxidative metabolism of artemisinin.  
The major pathways of artemisinin hydroxylation and deoxylation are illustrated 
 
 
Figure 23. Artemisinin kinetics in human liver microsomes. 
Kinetics for the disappearance rate of artemisinin in human liver microsomes 
(HLM). An increasing concentration of artemisinin (10 – 1000 µM was incubated in 
HLM (0.1 mg/ml) and an NADPH-generating system for 2 min at 37 oC. The figure 
shows curves for the rate of disappearance of artemisinin versus artemisinin 
concentration where data were fitted into the Michaelis-Menten equation. Each data 
point represents the mean of triplicate incubations.  
 
 
3.4.2 Inhibition of artemisinin’s metabolism by antiretrovirals.  
The effect of various antiretroviral agents (RTV, SQV, NLF and NVP) on the rate of 
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disappearance of artemisinin was investigated (Figure 24). As shown, RTV (0.1 to 
100 μM) showed significant inhibition of the metabolism of artemisinin. SQV (0.3 to 
100 μM) reduced the metabolism of artemisinin to 23.7 – 37.8 % of control, but 
significant inhibition was not observed. NVP (0.1 to 300 μM) showed potent 
inhibition to artemisinin’s metabolism at 0.1, 1, 100 and 300 μM.   
 
 
 
Figure 24. HIV antiretroviral influence on the metabolism of artemisinin 
Effect of the antiretrovirals- Saquinavir (SQV), Ritonavir (RTV), Nevirapine (NVP) 
and Nelfinavir (NLF) on the rate of metabolism of artemisinin expressed as a 
percentage of the control. Panel B illustrates their influence at concentrations < 
10µM 
 
 
3.4.3 Contribution of CYP3A4 to the metabolism of artemisinin in HIM.  
CYP2B6 and 3A4 are known to be the main enzymes responsible for the 
metabolism of artemisinin. In the study, the contribution of CYP3A4 was examined 
using ketoconazole (KTZ), a potent CYP3A-selective inhibitor.  In order to ascertain 
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the contribution of intestinal CYP3A enzymes to artemisinin’s metabolism, the 
percentage of artemisinin remaining unmetabolized after incubation with KTZ (0, 
0.1 and 1 µM) in HIM was examined. Figure 25 illustrates the percentage of 
artemisinin unmetabolized after a 10-min co-incubation period. The presence of 0.1 
and 1 µM KTZ, contributed ~6-49 % respectively to the intestinal metabolism of 
artemisinin, in comparison to that obtained in the absence of the inhibitor. At 
concentrations of 1 µM or less, CYP3A is the main enzyme inhibited. Also, 80 % of 
artemisinin was metabolized in the absence of KTZ. In humans, KTZ plasma 
concentration ranges from 1.4 to 4.5µM 195). 
 
 
Figure 25. CYP3A contribution to the intestinal metabolism of artemisinin. 
Plot estimating the relative contribution of CYP3A to the intestinal metabolism of 
artemisinin in human intestinal microsomes (HIM). 0, 0.1 and 1µM ketoconazole 
was incubated in HIM (0.1 mg/ml) and an NADPH-generating system for 10 min at 
37 oC. The figure shows the percentage of the disappearance rate of artemisinin. 
Each data point represents the mean of triplicate incubations.  
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4. DISCUSSION 
4.1 PAPER I 
The inhibition and induction of transporters that mediate the uptake and efflux of 
xenobiotics are important mechanisms underlying DDIs. The P-gp transporter is 
known to modulate intestinal absorption of its substrates. The expression of P-gp on 
the apical membrane of mucosal cells may play an important role in extruding orally 
administered drugs into the intestinal lumen, resulting in lower bioavailability of 
pharmaceutical agents. Therefore, the potential of intestinal P-gp-mediated DDIs of 
antimalarials with P-gp substrates was examined in this study. The test 
concentrations of the antimalarials (100 µM and 1 mM) were chosen to simulate 
theoretical drug concentrations in the gut, which were determined in the present 
study to be 5.16 mM for ADQ, 2.08 mM for ART, and 3.63 mM for LUM. These 
theoretical concentrations were calculated by dividing the maximum therapeutic 
dose by 250 mL (assuming complete dissolution in a glass of water)196). VER, a 
widely used P-gp inhibitor, was employed as a positive inhibitor control at a 
concentration of 100 µM.  
A preliminary screening was first carried out using seven antimalarial drugs in a 
Rho-123 transport assay to investigate their potential as P-gp inhibitors or 
non-inhibitors. Of the seven antimalarials initially screened, ART, ADQ, and LUM 
showed the most efficacious blockade of Rho-123 transport in the B-A direction 
across a Caco-2 cell monolayer. This observation confirms previous reports that 
demonstrated an inhibitory effect of ADQ against P-gp-mediated transport in 
Caco-2 cells, as well as an inhibitory effect of ART in K562/adr and GLC4/adr 
resistant cell lines 197, 198).   
Next, the impact of ART, ADQ, and LUM on DIG transport was evaluated. In this 
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study, all three antimalarials inhibited DIG transport at concentrations of both 100 
µM and 1 mM. ADQ and ART (1 mM) exhibited potent inhibition that was 
comparable with that of VER (100 µM). Under the conditions of this study, LUM was 
shown to be a relatively weak P-gp inhibitor, even at a concentration of 1 mM. This 
was further exemplified by the similar ERs obtained with LUM at 100 µM and 1 mM 
(7.6 and 7.5, respectively).  
FXD (the active metabolite of terfenadine) is commonly used as a P-gp probe agent 
with minimal hepatic and enteric biotransformation. Due to the increase in the 
global incidence of allergic diseases, there is an increased potential for drug 
interactions involving FXD. Evidence to support the role of human organic anion 
transporting polypeptide (OATP) drug uptake transporters and the drug efflux 
transporter, P-glycoprotein (P-gp) in the cellular uptake and excretion of FXD  has 
been reported 185). Some recent studies have implicated MRP2 and MRP3 in FXD 
transport 199-201). Although a  review of clinical trials indicates that grapefruit juice, 
orange juice and apple juice can reduce oral bioavailability of FXD with a potential 
of reducing pharmacodynamic effects of FXD, the clinical importance of the 
interaction is not clearly established 202). Elevated FXD concentrations in volunteers 
co-administered FXD together with erythromycin or ketoconazole has been well 
described. These results and other recent evidence show that these drug 
interactions occur through non-CYP-mediated mechanisms 203). In this study, at 
anti-malarial concentration of 100µM, LUM exhibited non-significant inhibitory 
effect on FXD transport. Both ADQ and ART inhibited FXD transport when 
co-administered. However at 1000µM anti-malarial concentration, ART and ADQ 
enhanced FXD transport. Its mechanism is unclear however a plausible mechanism 
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may be due to the contribution of multiple transporters including P-gp, OATP, MRP2 
and MRP3 mediation 204). A similar increase in basolateral-to-apical FXD transport 
was reported when co-administered with 10µM erythromycin as well as 1µM and 
10µM Rifamycin possibly due to the inhibition of both OATP and P-gp. However 
inhibition of OATP and P-gp caused a reduction in apical-to-basolateral transport of 
FXD 205). Estrone-3-sulphate also decreased the apical uptake of FXD 204). Inhibition 
of efflux transporters including MRP3 may result in increase in basolateral-to-apical 
transport with minimal effects on apical-to-basolateral transport. An explanation of 
the contribution of uptake and efflux transporters on FXD in Caco-2 cell monolayers 
is illustrated in Figure 26. 
 
Figure 26. Transporters modulated by fexofenadine in Caco-2 cells 
 
In FXD transport, MRP3 plays an important role in its basolateral-to-apical transport 
while P-gp and OATP are vital for its apical-to-basolateral transport. Due to the 
contribution of various transporters to FXD, an inhibition of uptake transport on the 
apical membrane or an inhibition of the efflux transporter on the basolateral 
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membrane will result in a decrease in the Papp A-B as well as an increase in Papp B-A as 
observed with some concentrations of the antimalarials. However, the involvement 
of P-gp in drug interactions might be difficult to prove in humans due to the 
overlapping substrate specificity of inducers and inhibitors of CYP3A4 and P-gp and 
also because some drug interactions involve CYP3A4 enzymes, P-gp as well as other 
transporters. 
Tachibana et al.126) described the DIN as an index for predicting DDI potential (Eq. 3, 
section 2.1.4). It was reported that P-gp inhibitors with a DIN below 10.8 have a low 
risk of interacting with P-gp substrates, while those with a DIN above 27.9 present a 
high risk. Therefore, the DINs for the potential interaction of the antimalarials with 
DIG were calculated. From these determinations, the DIN for ADQ (46.7) suggests a 
high potential for DDIs involving ADQ. The calculated DIN for ART was 12.6, 
suggestive of moderate DDI risk. LUM had a DIN of 0.7, suggestive of low DDI risk. 
This implies that, although all three antimalarials inhibited P-gp-mediated DIG 
transport under the study conditions, there may be a higher risk of clinically 
relevant DDIs with ADQ and ART than with LUM. Since a higher DIN tends to 
correlate with a higher AUC ratio 126), it may cause toxicity when drugs with narrow 
therapeutic indices are involved. In addition, there is a likely increase in 
bioavailability when P-gp substrate drugs are co-administered with ADQ or ART. 
DIN as an index for predicting DDI potential is similar to FDA’s draft guidance. For 
P-gp interactions, the guidance recommends an evaluation for potential clinical 
DDIs when [I2]/ IC50 is greater than or equal to 10 206). Here, [I2] is the theoretical 
maximum gastrointestinal concentration. ADQ besides being used as an effective 
antimalarial especially in chloroquine-resistant malaria is also known to possess 
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potent anti-inflammatory and antipyretic properties. There is therefore the 
potential of several DDIs occurring.  In addition, ART (which has a moderate DDI 
risk from the computed DIN) belongs to the class of artemisinin-based antimalarials, 
which is WHO’s recommended first line therapy when used in combination with 
other antimalarials. It is therefore widely used and may pose a higher intestinal DDI 
potential when orally administered due to the higher exposure levels in the 
intestine. 
In clinical settings, P-gp has been implicated in the disposition of some human 
immunodeficiency virus-1 (HIV-1) protease inhibitors (e.g., amprenavir, indinavir, 
nelfinavir, and saquinavir) 207, 208). Because malaria and HIV share a wide overlap in 
their socio-economic and geographical areas of occurrence, many locales with a 
high malaria burden also have high a HIV burden. Thus, co-administration of 
antimalarials with antiretroviral drugs is common. Therefore, there might be an 
increased likelihood of DDIs when HIV protease inhibitors are co-administered 
with LUM, ART, and ADQ, which may in turn require dose adjustments of the 
antimalarial or the antiretroviral agent, or both. In addition, colchicine, a drug used 
to treat gout and a well-known P-gp substrate, may be co-administered with 
antimalarials such as CQ, which can also be used to treat gout. Colchicine is 
notorious for its narrow therapeutic index, and hence DDIs with antimalarials may 
result in an increased risk of colchicine-induced toxicity. This potentially clinically 
relevant DDI may also require dose adjustments 209). 
Previous studies have shown that some antimalarial drugs exhibit low absorption 
after oral administration, leading to their classification as P-gp substrates or 
inhibitors 210-212). Current malaria treatment guidelines recommend combination 
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therapy, preferably ART-based 213) Thus, ART (as well as ADQ and LUM) are 
clinically used in combination with additional antimalarial drugs and 
non-antimalarial drugs that, as described above, may be P-gp substrates. This could 
result in unexpectedly high therapeutic outcomes for the co-administered drug, 
again necessitating dose adjustments to maximize therapeutic efficacy. Although 
several clinical reports detail treatment failure and antimalarial drug resistance, 
these reports have mainly emphasized mutations that mediate resistance in 
malarial parasites 214-216). However, the current study brings new light to the fact 
that altered therapeutic outcomes might be due to DDIs between these antimalarials 
and other drugs that interact with P-gp. Poor oral bioavailability (as is the case with 
most P-gp substrates) with a resultant wide range in blood drug levels will favor the 
emergence of resistance because doses are mainly chosen based on therapeutic 
ratios. Co-administration of antimalarial P-gp substrate drugs with antimalarials that 
are P-gp inhibitors may improve oral bioavailability of the former and thereby 
reduce doses that are needed to clear infection 217). This is expected to reduce the 
cost of therapy, as well as the emergence and spread of resistance.  
 
4.2 PAPER II 
In recent years, there has been a global increase in the demand for plant derived 
products. However there are only few reports on potential of these phytomedicines 
interacting with transport proteins. In this study the potential of phytomedicines 
commonly used for malaria treatment to encounter a p-glycoprotein mediated 
intestinal interaction was examined as it is known that many patients on 
conventional malaria therapy alter their diets, include supplements or 
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phytomedicines with an aim of achieving better therapeutic outcomes 93). Here, 
whole herbal extracts were used rather than isolated constituents. This is because 
most herbal remedies are taken whole as a mixture of constituents and not just as 
isolated components 218, 219). Also, there is an uncertainty over the particular 
component that may be implicated in a drug interaction. For the selection of test 
doses, the test concentrations of 0.02, 0.2, 1, 2, 5, 10, and 20 mg/mL of the extracts 
were used to simulate theoretical intestinal concentration. This was obtained by 
dividing the highest recommended daily doses in literature by 250mL (anticipating 
complete dissolution of the dose in 250mL of water) 196). Since P-gp inhibitors when 
orally administered are known to cause high levels of exposure in the intestine and 
may cause DDIs in the intestine rather than in the liver, higher doses of 1mg - 
20mg/mL are more likely to be the relevant intestinal concentration range of these 
phytomedicines while lower doses may relate to the plasma concentration. 
From the initial B-A studies, CUR, VA, CP, and ML at almost all the concentrations 
investigated exhibited significant inhibition of 3H-DIG mediated P-gp transport with 
ML being the most potent inhibitor. Transport of DIG in the A-B direction was 
enhanced by VA, CP and ML as well as the P-gp inhibitor VER. This increase further 
suggests their P-gp inhibitory role. On the other hand NL, LG and MLB did not 
significantly inhibit B-A 3H-DIG mediated P-gp transport. 
ML showed significant concentration-dependent inhibition to P-gp-mediated 
transport of DIG at 0.02 - 20 mg/ml. Another specie of mistletoe- Viscum album has 
previously been suggested to be an inhibitor at concentrations below 0.022mg/mL 
220). It is also very well known for its use in cancer therapy and epilepsy 221). In 
addition to some antimalarials which are P-gp substrates (quinine, chloroquine, 
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quinidine), several orally administered anticancer agents (etoposide, tamoxifen, 
topotecan, everolimus, imatinib, lapatinib, nilotinib) are also P-gp substrates. Hence, 
there may be a higher likelihood of drug interactions on co-administration of ML 
with some of these conventional antimalarial or chemotherapeutic agents especially 
as some of them have narrow therapeutic indices. These interactions are expected 
to affect therapeutic outcomes which may be either beneficial or detrimental to the 
patient. 
Although there are well documented reports on the ethnopharmacological use of VA 
for malaria 222) and for its potent hypoglycaemic effects in diabetes mellitus 223), this 
is the first known report on its interaction with P-gp. In this study VA significantly 
(p < 0.01) inhibited P-gp at 1 - 20 mg/mL. There were increases in mean A-B 
transport at all concentrations examined. This further suggests the P-gp blockade 
effect of VA. Conventional antidiabetic and lipid lowering drugs that are P-gp 
substrates and which may be concomitantly used with VA include glyburide, 
sitagliptin, saxagliptin and glibenclamide. An interesting observation is VA’s 
extensive use as a vegetable in diets in various regions in Africa. These factors are 
expected to cause drug-phytomedicine and drug-food interactions which previously 
might have been noticed but the underlying mechanism uninvestigated. 
There are several reports on the ethnomedicinal uses of CP leaves. Evidence for the 
use of its decoctions as an antimalarial, cancer therapeutic, antihelminthic, 
antioxidant abounds in literature 82, 224). This suggests the possibility of toxicity 
when CP leaves and conventional P-gp substrate drugs are co-administered.  In this 
study, curcumin at test concentrations of 0.02mg/mL - 2mg/mL showed significant 
inhibition to P-gp mediated DIG transport. However at 20mg/mL, there was a 
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non-significant increase in B-A DIG transport. Its A-B transport was not investigated 
as earlier reports on the P-gp inhibitory effect of curcumin in multidrug resistant 
human cervical carcinoma cell line KB VI, L-MDR1 and LLC-PK1 have been 
documented previously 225-227). Also, findings from the MTT assay showed that VA 
exhibited increases in cell viability in comparison with HBSS control which was 
significant at 1mg/mL (p < 0.05) and 5mg/mL (p < 0.01) suggestive of its possible 
cytoprotective effect.  Its hepatoprotective effect has been previously reported 228). 
ML at 5 and 10mg/mL also showed significant (p < 0.05) increase in cell viability. In 
this study however, these observations are not expected to significantly affect cell 
functionality.  
 
4.3 PAPER III 
The efflux transporter P-gp is highly expressed in the intestinal tract where it 
extrudes drugs, toxins, and xenobiotics. The pharmacokinetic changes arising from 
concomitant administration of drugs with P-gp modulators may cause beneficial or 
detrimental drug interactions. Therefore, drugs and herbs that interfere with P-gp 
can be clinically important in modifying the bioavailability, pharmacokinetic 
disposition, and safety profiles of substrate drugs.  
The herbs CP, VA, and ML, are popular ethnomedicines with clinical significance 
that are widely used in certain countries and continents. VA and ML are commonly 
used in tropical Africa. Other species of Vernonia are medicinally used in the 
Americas and parts of Asia. Although CP originated from Central America and its 
fruit is mainly consumed there, several studies report that its leaves are used as a 
herbal medicine in vast regions of the world. These herbs function as 
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antihelminthics and are used to treat cancer, malaria, diabetes mellitus, fevers, 
allergic and gastrointestinal disorders 224, 229-231). Multi-center clinical trials of VA 
have been initiated 222).  
We initially examined the influence of seven herbs on the bidirectional transport of 
digoxin using a Caco-2 cell monolayer model 81). The transport of digoxin in the 
apical-to-basolateral direction was significantly enhanced by VA, CP, and ML, as well 
as the P-gp inhibitor VER. Furthermore, the basolateral-to-apical transport of 
digoxin was significantly inhibited by these herbs. These results suggested that ML, 
CP, and VA inhibit P-gp. A cell viability assay indicated that these in vitro effects 
were not due to cytotoxicity. The present study was designed to further investigate 
these findings by examining the effects of VP, VA, and ML on the modulation of 
P-gp in ex vivo and in vivo models using digoxin as a clinically relevant substrate.  
The present study used crude herbal extracts, rather than single components 
isolated from the herbs, because patients generally take whole herbal products, 
usually containing several constituents. Consequently, crude extracts may contain 
additional components that can affect P-gp, besides their pharmacologically active 
components. Studies on drug disposition are complicated by the overlapping tissue 
distributions of CYP3A4 and P-gp, and the broad spectrum of their interacting 
substrates. Therefore, digoxin was chosen as the substrate in this study because it 
selectively interacts with P-gp but negligibly with CYP3A4 232. 
In the Ussing chamber study, CP significantly increased the mean apparent 
permeability (p<0.001), comparable with VER. However, the AUC did not 
significantly increase following oral administration of CP in rats. Ussing chambers 
containing rat intestinal segments provide a simple method to investigate 
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permeability, which highly correlates with absorption properties in humans 134, 233). 
However, despite the merits of Ussing chambers, some drawbacks have been 
reported. For example, Ussing chambers may underestimate drug transport because 
the drug needs to cross the entire intestinal wall, which might be rate-limiting, 
whereas this is not necessary in vivo 134). Furthermore, only rat ileum was used in 
Ussing chambers in this study and regional differences in intestinal absorption 
were not investigated. Also, in the rat model, tissue viability is not a limitation, as 
may be the case in an Ussing system. These factors may underlie the difference in 
the effects of CP observed in the two systems. Importantly, although the mucosal 
architecture is intact in the Ussing system, it may not behave exactly as the intact 
gut does 234). Although medicinal herbs are efficacious in the treatment of various 
ailments, the lack of standard prescribed dosages is a major concern 235). This may 
lead to the consumption of large quantities of herbs, resulting in their 
bioaccumulation and complications in humans. However, non-standardized doses of 
up to 6 cups (2 cups thrice) of aqueous extracts (approximately 20–40 g of plant 
material) are consumed daily by humans. We converted the estimated human dose 
to the equivalent dose in rats according to body surface area. Therefore, 90 mg/kg 
of all the studied herbs were administered to rats in this study 236).  
The effects of these herbs on the function of P-gp in vivo were investigated using 
male SD rats. Oral administration of VA enhanced the AUC and Cmax of digoxin. The 
T1/2 of digoxin was similar to that previously reported 237, 238). T1/2 did not 
significantly change when VA or VER were co-administered, which suggests that 
they increased the intestinal absorption of digoxin but did not affect its systemic 
elimination. The herbs affected digoxin transport within one hour of administration. 
97 
 
This suggests that digoxin absorption may be enhanced due to inhibition of 
intestinal P-gp. This is in agreement with the findings of the Ussing chamber study. 
No significant change in the total clearance of digoxin on co-administration with the 
herbs was observed. Organ blood flow, extraction ratio, and transporters influence 
the clearance and disposition of drugs 104). The in vivo study suggests that VA 
increases digoxin absorption more potently than VER; co-administration of VA or 
VER increased AUC (0-∞) 2.1- and 1.5-fold, respectively, compared to the control. This 
effect of VA is of particular importance because in addition to its potent medicinal 
value, it is also a common vegetable in the African diet. There is no known study 
reporting that VA may modulate the pharmacokinetics of drugs that are P-gp 
substrates. Hence, this finding may be of particular clinical relevance as it indicates 
a food-drug interaction may also occur. Digoxin is a substrate of P-gp, and this 
interaction results in the extrusion of digoxin from enterocytes throughout the 
intestinal mucosa into the gut lumen. Consequently, the P-gp inhibitor VER 
reduced the intestinal secretion of digoxin. VA inhibited the secretion of digoxin 
more than VER. It is thought that these herbs and P-gp compete for binding to 
digoxin and this underlies the changes in digoxin disposition observed following 
its co-administration with herbs.  
Extracts of VA have very high concentrations of flavonoids 239). There is increasing 
evidence that flavonoids can inhibit P-gp. Flavonoids obtained from the diet or 
supplements can alter P-gp levels and thereby affect the oral availability of drugs 
that are transported by P-gp 240, 241). The flavonoids kaempferide, quercetin, 
apigenin, naringenin, genistein, and rutin are reported to affect P-gp activity 
through various mechanisms including direct interaction with the vicinal 
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ATP-binding sites, the steroid-binding site, or the substrate-binding domains, or via 
a heterotropic allosteric mechanism 242). Similarly, the in vivo absorption of 
nitrofurantoin is enhanced following administration of the flavonoid chrysin due to 
modulation of transporter function 243). Several other flavonoids including silymarin, 
morin, biochanin A, and phloretin modulate P-gp 244, 245). Therefore, the high level of 
flavonoids in the herbal extracts may be responsible for the inhibition of P-gp. The 
bioactive phytochemicals in VA include flavonoids (luteolin, 
luteolin-7-O-β-glucuronoside, and luteolin-7-O-β-glucoside), bitter sesquiterpene 
lactones, tannins, and steroid glucosides 246, 247). Because of the common backbone 
flavone structure of luteolin as illustrated in Figure 27 and other flavonoids which 
have shown P-gp inhibition, the observed effect may be partly contributed by 
luteolin. CP is rich in carpaine, pseudocarpaine, dehydrocarpaine I and II, choline 
and carposide alongside flavonoids (quercetin and kaempferol) that are found in the 
leaves 248, 249). Hydrolysable tannins, terpenes, saponins, and flavonoids are abundant 
in mistletoe leaves 250).  
 
Figure 27. Flavonoids as inhibitors of P-glycoprotein 
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ML is a species of mistletoe. Other mistletoe species including Viscum album have 
been reported to potently inhibit P-gp 220). In our previous research using Caco-2 
cells, treatment with 2-20 mg/ml ML significantly inhibited P-gp, with similar 
potency to treatment with 100 µM VER. The reason why ML did not inhibit P-gp as 
potently in the present study may be because the expression of drug transporters 
and permeability varies between Caco-2 cells and the human intestine. Cmax, AUC0-3, 
and AUC (0-∞) of digoxin were increased in the presence of VA in comparison to the 
control. In addition, the systemic clearance of digoxin was reduced following 
treatment with ML and VER; however, this was not statistically significant. These 
results are consistent with a study investigating the HDI potential of curcumin when 
co-administered with celiprolol and midazolam 251). A similar study reported that 
co-administration of VER decreases the clearance of digoxin 252). 
Inhibition of P-gp by VA increased the digoxin plasma concentration after a single 
oral dose, which is in agreement with the previous in vitro results. This effect was 
observed within the first hour after administration, suggesting that VA mainly 
affects the absorption of digoxin. The findings suggest that VA could have 
beneficial roles, especially as adjuvants in cancer chemotherapy and diabetes 
treatment. Complementary and alternative forms of treatment are utilized by 
many patients in addition to well-established conventional treatments for several 
medical ailments. Thus, it is important to investigate the likelihood of changes in 
drug disposition when conventional and alternative medicines are 
co-administered. The majority of anticancer agents are P-gp substrates that many 
cancers are resistant to; therefore co-administration with VA may increase the oral 
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bioavailability of these agents or promote MDR reversal. The hypoglycaemic 
agents, glyburide, saxagliptin, sitagliptin, and linagliptin have some P-gp substrate 
activity 253, 254). The potential risk of HDIs occurring with VA is thought to be high 
since it is commonly used to treat diabetes mellitus alongside conventional 
medicines. Caution may need to be exercised when drugs with narrow therapeutic 
indices are co-administered, such as digoxin, as this may result in toxic responses. 
When herbs are used as adjuvants in cancer therapy they can provide support to 
patients being treated with conventional medicines by alleviating side-effects and 
improving self-defense and quality of life 241, 255). P-gp inhibitors, including 
tariquidar, GF120918, and biricodar, are used as adjuvants in cancer therapy 
256-258). Doses adjustment may be necessary in clinical situations and caution is 
recommended. Our findings indicate that HDIs need to be investigated further to 
obtain a more detailed understanding of their impact in human subjects and to 
ensure appropriate clinical intervention when they are co-administered with 
conventional P-gp substrate drugs. Also as illustrated in Table 8, significant in vitro 
inhibition of P-gp may not translate to significant inhibition in animal models 
 
Table 8.   Summary of herb-drug interactions using different study models. 
 
 
 
Key: -, Non inhibition +, non significant inhibition +++, significant inhibition          
n.d, not determined] 
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4.4 PAPER IV 
Artemisinin is mainly metabolized by the CYP system in the liver with less than 1% 
being excreted unchanged in the urine 259). It is also known to induce the in vivo 
enzymatic activity of CYP2C19 and -2B6. Therefore, it is both a substrate and an 
inducer to CYP2B6, inducing its own metabolism in both patients and healthy 
subjects 260). It is also postulated to induce the expression of CYP by activating 
pregnane X receptor (PXR) as well as constitutive androstane receptor (CAR). 
Figure 28 illustrates the modulation of CYP by the various drugs investigated. 
 
 
Figure 28 CYP modulation by artemisinin and the investigated antiretrovirals 
 
The Vmax and Km obtained in this study are higher than a previous report which 
utilized rat microsomal proteins 261). However, this study reports values obtained 
from the overall disappearance of artemisinin, rather than that for metabolite 
formation. In addition, this study utilized Michaelis-Menten kinetics rather than 
first order kinetics which has been reported to be a better measure for the hepatic 
microsomal metabolism of ASN 262). In this study, KTZ at concentrations of 0.1 – 10 
102 
 
µM were used in order to examine the contribution of CYP3A to the metabolism of 
artemisinin. It is known that high concentrations of >10 µM inhibit not only CYP3A 
but also other CYPs 263, 264). A previous report had shown that in individual HLMs, 
orphenadrine (a CYP2B6 inhibitor) inhibited the metabolism of artemisinin by 
45-75 %. In addition, 4 µM KTZ inhibited artemisinin’s metabolism by 46 % in 
pHLM 265). 
The HIV protease inhibitors are known to have differential effects (inhibition, 
inactivation or induction) on CYP isozymes with RTV and SQV showing inhibition to 
CYP3A4 and -2C9 266). The NNRTI, NVP inhibits CYP3A4, -2C9, and -2C19. Also, the 
CYP2B6 inhibitory effect of NLF and RTV has been reported 267). Although not 
investigated in this study, this ability of artemisinin to induce its own metabolism 
through inducing the xenosensors PXR and CAR may be of clinical significance 
especially as the HIV antiretrovirals are substrates of various CYPs. This could alter 
the pharmacokinetic disposition of both the antiretrovirals and artemisinin itself.  
In comparison to other CYP3A inhibitors, RTV and SQV are potent inhibitors of 
CYP3A as demonstrated in HLM for the inhibition of midazolam-1-hydroxylation and 
the 6β-hydroxylation of testosterone. NVP has shown a Ki of 31 µM to CYP3A4 in 
HLM 268). Furthermore, RTV has been shown to be a potent CYP2B6 inhibitor with a 
Ki of 5 µM to bupropion hydroxylation 269). Daily doses of RTV (600mg twice daily) 
and NVP (200mg twice daily) produces a maximal steady state plasma 
concentration of 11 ± 4 µg/ml and 4.5 µg/ml respectively 270, 271). These values 
correspond to 15.2 ± 5.5 µM and 8.8-19.9 µM which falls into the range of 
concentrations examined.  
RTV is known to be a potent inhibitor of CYP3A using nifedipine oxidation (IC50 = 
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0.07 μM) and terfenadine hydroxylation (IC50 = 0.14 μM) as metabolic probes 272). 
However in this study, only the effects on CYP3A, -2B6 and -2A6 are of relevance as 
these are the main CYP isoforms involved in artemisinin’s metabolism. The findings 
show that RTV exhibited very potent inhibition to the metabolism of artemisinin 
with 73-84 % of artemisinin remaining unmetabolized on co-incubation. This is 
thought to be as a result of the simultaneous blockade of CYP3A4 and -2B6 which 
are the main pathways for artemisinin metabolism. 
NVP has been shown to be a CYP3A inhibitor with an IC50 of 106 and 250 μM using 
triazolam hydroxylation with or without pre-incubation, respectively 273). Wen et al. 
268), reported a Ki value of 31 μM to CYP3A4 in HLM which further buttresses the 
significance of the NVP concentrations examined.  Similar to the protease inhibitor 
RTV, NVP a NNRTI exhibited potent inhibition to the metabolism of artemisinin. 
However, 10 µM NVP showed a large increase in the amount metabolized.  
However, it should be noted that apart from being a potent CYP3A inhibitor and 
substrate; nevirapine has also been reported to be a potent inducer of CYP3A and 
-2B6 in both in humans 274-276). Therefore, in clinical situations, its induction effect 
may be significant. Although it is known that transcriptional and 
post-transcriptional regulation cannot be evaluated by the use of microsomal assays, 
the enhancement of CYP activity has been observed 277). An enhancement of 
CYP2B6 and -3A activity may be responsible for the effect observed on 
co-incubation at 10 and 30 µM. This is because artemisinin is mainly metabolized 
by CYP2B6, an increase in its metabolism via inducing CYP2B6 and -3A4 by NVP 
will result in a lower amount of artemisinin remaining. We are of the view this 
partial inhibition of the metabolism of ASN may be due to a net enhancement of 
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CYP2B6 and -3A4 rather than enzyme inhibition. At the other concentrations, it is 
thought that net inhibition/ inactivation of CYP3A4 plays the major role.  
NLF and SQV mainly showed non-significant effect on the metabolism of 
artemisinin. Apart from being a CYP3A4 and -2B6 inhibitor 267), NLF also induces 
CYP2B6, -3A4, -2C9 and -2C19. It is also a substrate of CYP3A4 and -2C19. There is 
also a report on its -1A2 and -2E1 potential 278-281). The net contribution of these 
CYP isoforms did not seem to significantly affect the in vitro metabolism of 
artemisinin in this study. The insignificant inhibitory effect on artemisinin’s 
metabolism by NLF is thought to be as a result of net enhancement of CYP2B6. SQV 
on the other hand inhibits CYP3A4, with minimal effects on other CYPs. In addition, 
saquinavir weakly binds PXR and activate its target genes 282). However, under the 
conditions of this study, the likelihood of encountering a DDI on co-administration 
of either SQV or NLF with artemisinin is low.  
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5. CONCLUSION 
5.1 PAPER I 
In conclusion, the current findings show that ART, ADQ, and LUM decreased 
P-gp-mediated transport across Caco-2 cell monolayers. Although DIG was used as a 
representative P-gp substrate in this study, there may be a potential for DDIs 
between certain antimalarials and P-gp substrates in general. These interactions 
may be of clinical relevance given the high incidence of co-administration of P-gp 
substrate drugs with antimalarials. Thus, the present study is anticipated to provide 
useful information that will lead to more effective treatment policies for malaria. 
However, further in vivo investigations are recommended to confirm the in vitro 
findings. 
5.2 PAPER II 
The results from this study may provide better understanding to the effect of 
phytomedicines intervention on concomitant conventional drug administration. In 
conclusion, the present study has shown that CP, VA and ML are transport inhibitors 
of P-gp in Caco-2 cells and particular caution should be observed when they are 
ingested with other P-gp substrate drugs as they are expected to enhance the 
absorptive transport of P-gp substrate drugs. Because dose standardization is 
usually a problem with herbal remedies, the need for well controlled trials, 
improved regulation and global harmonization in the use of phytomedicines is of 
paramount importance to ensure their optimal safety and efficacy. Although this in 
vitro investigation gives valuable information, further in vivo studies may be 
required to verify the clinical relevance since in vivo investigations of possible 
interactions may be more complicated and may bring into play the effect of 
enzymes, pH, etc. that are not considered in an in vitro study. 
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5.3 PAPER III 
In conclusion, the observed changes in the pharmacokinetics of digoxin and the 
absorption profile from the Ussing chamber study indicate that VA 
co-administration appears to pose a more clinically significant risk for P-gp 
mediated HDIs than either CP or ML. The series of investigations spanning in vitro 
to ex vivo to in vivo studies in rats confirm the P-gp inhibitory effect of VA. 
Importantly, the study has shown that significant in vitro P-gp inhibition may not 
translate to inhibition in animal models. Our findings point to the need for further 
assessment of HDIs in order to obtain a more detailed understanding of their impact 
in human subjects and to ensure appropriate clinical intervention when they are 
co-administered with conventional P-gp substrate drugs. 
5.4 PAPER IV 
Our in vitro study has shown the potent inhibitory effect of RTV and NVP on the 
main metabolic pathways of artemisinin at clinically significant concentrations. In 
view of this, DDIs should be considered on co-administration with artemisinin. The 
antiretroviral concentrations utilized in this study are within the usual plasma 
concentration range, suggestive of the potential of clinically relevant DDIs occurring 
on co-administration of especially RTV or NVP with artemisinin 
Nowadays, a mechanistic approach to evaluating DDIs can be achieved by 
extrapolating findings from clinical studies to other drug classes metabolized by the 
same isoforms.  Taken together, in vitro data from this study is strongly suggestive 
of the influence of RTV and NVP on CYP2B6 and -3A4 mediated metabolism of 
artemisinin.  
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5.5 GENERAL CONCLUDING REMARKS 
Herbal medicines are currently in high demand, and their popularity is steadily 
increasing. Because of their perceived effectiveness, fewer side effects, and 
relatively low cost they are being used in the management of numerous medical 
conditions. However, they are capable of affecting the pharmacokinetics and 
pharmacodynamics of co-administered conventional drugs. These interactions are 
particularly of clinically relevance when metabolizing enzymes and xenobiotic 
transporters, which are responsible for fate of many drugs, are induced or inhibited. 
The effect of HDIs could be of benefit or deleterious to the patient. The use of herbal 
medicines is increasing, possibly due to their widespread promotion in the media 
as well as unsubstantiated health care claims. Although herbal medicines are 
beneficial, despite popular belief, they are not completely harmless and HDIs may 
occur on concomitant use with conventional drugs, but many possibly go unnoticed 
due to various factors.  It is safer to view them as unrefined pharmaceuticals, 
capable of producing physiologic change, for better or worse.  
Most herbal remedies, unlike conventional drugs comprise a complex mixture of 
chemical constituents.  In order to better understand the detection and handling of 
HDIs, an expansion on knowledge on phytochemicals in herbal medicines is 
essential. Presently in most cases, complete characterization of the bioactive 
compounds is not well defined, information on toxicity and adverse effects are 
insufficient. It is expected that standardization, including chemical fingerprinting 
would become potent tools for quality control of herbal medicines. However, 
because most of the available HDI information is based on individual case reports, 
animal studies and in vitro data, extensive research is required to confirm and 
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assess the clinical significance of these potential interactions. HDIs may be 
under-reported and appropriate pharmacovigilance requires the collective 
responsibility of the patient, the health practitioner and researchers.  
In this review, both pharmacokinetic (drug metabolizing enzymes and drug 
transporter systems) and pharmacodynamic mechanisms have been considered to 
play a role in these interactions. There are reports on the inductive role of PXR as a 
nuclear receptor, however it is of importance to research into other receptors; 
constitutive androstane receptor (CAR), and vitamin D-binding receptor (VDR), as 
these may also play an integral role in the mechanism of inductive processes 
involved in HDIs. Numerous conventional medicines have been developed from 
plants and because of the demerits of some conventional drugs, there is an active 
search for new drug development from plants. Future perspectives for the 
application of HDIs are in new drug development, use of herbal medicines as 
adjuvants to conventional drugs. They may also be used for their additive or 
synergistic effect when co-administered with modern medicine. This may require a 
decreased dose of the conventional drug, and possibly result to reduction in the 
manifestation of side effects. In particular, patients taking drugs with a narrow 
therapeutic index should be discouraged from using herbal products because of the 
ease of toxicity or ineffectiveness.  
In conclusion, HDIs certainly occur and may have serious consequences. However 
because they are under-researched, present knowledge is incomplete. It is worth 
mentioning that the further research and controlled clinical studies are needed to 
clarify and determine the underlying mechanisms for these altered drug effects.
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APPENDIX 
 
 
Chemical structures of the HIV antiretrovirals, P-glycoprotein substrates and inhibitors 
utilized in the study. The structure of artemisinin and its derivatives are shown. 
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